Search this site

The Contrarian Mandate in Healthtech: The Power of a Human-Centric Narrative in an AI-First World Executive Summary The health technology sector is experiencing a period of intense focus on artificial intelligence, driven by an "AI-first" narrative that has captivated investors and dominated industry discourse. This report posits that this concentrated market behaviour, characterised by an investment "gold rush," presents a profound opportunity for a contrarian business strategy. The prevailing AI narrative, much like other market frenzies, has led to a collective overvaluation of a single technology and its perceived benefits, while simultaneously undervaluing more fundamental, human-centric solutions. The true market need is not for more AI, but for proven, trustworthy and seamlessly integrated solutions that prioritise tangible human outcomes. A successful and durable healthtech business can be built by explicitly embracing a "non-AI story." This strategy leverages the inherent vulnerabilities of the AI-first model, including its unproven return on investment, ethical and regulatory risks, and deep-seated human distrust, to create a defensible, problem-first, and trust-centric value proposition. This is not a rejection of technological progress but a strategic re-framing of it as a powerful enabler, not the core promise. By focusing on a nuanced, human-in-the-loop approach and building competitive moats in integration and distribution, a company can carve out a sustainable path to success in a market intoxicated by hype. The Current HealthTech Landscape: An Analysis of the AI-First Narrative The Investment "AI Gold Rush" of H1 2025 The digital health sector has emerged as a rare bright spot within a broader healthcare investment landscape that has seen a significant slowdown. In the first half of 2025, digital health startups in the United States and Europe collectively raised $6.4 Billion, representing an increase from the $6 Billion raised in the first half of 2024. However, a closer look at this funding activity reveals a highly concentrated and potentially imbalanced market dynamic. While the overall amount of capital increased, the number of fundraising deals decreased to 245, a notable drop from 273 in the first half of the previous year. This trend could lead to the lowest overall deal count since 2020, suggesting that capital is being funnelled into a smaller number of larger, later-stage rounds. This pattern is almost entirely attributable to the overwhelming investor excitement surrounding artificial intelligence. Startups that identify as AI-enabled captured a disproportionate share of this funding, securing 62% of all digital health venture capital, or $3.95 Billion dollars. The funding disparity is particularly striking at the individual deal level, where AI-enabled startups raised an average of $34.4 Million dollars per round, an 83% premium over the $18.8 Million dollars raised by their non-AI counterparts. The consolidation of capital is further underscored by the fact that nine of the 11 "mega-deals," defined as rounds over 100 million dollars, were awarded to AI-enabled companies. This data indicates that venture capitalists are not merely pro-AI; they are exhibiting a herd-like behaviour where a fear of missing out on the next big AI winner drives investment decisions. As a result, non-AI companies, regardless of their intrinsic value, may find themselves systematically starved of capital, making a compelling and differentiated narrative a matter of survival. This creates an environment where the market is overpricing "hot" stocks and underestimating the value of companies that do not fit the dominant narrative. The Prevailing Value Proposition: A Focus on Efficiency and Automation The dominant "AI-first" narrative is built on the promise of solving some of healthcare's most pressing systemic challenges, such as rising costs, persistent workforce shortages, and operational inefficiencies. The primary value proposition centres on using technology to automate and augment human tasks. This is a story of efficiency, not of empathy or human connection. Key AI use cases that embody this value proposition include: Clinical and Non-Clinical Workflow: Tools like ambient listening and machine vision are being deployed to reduce the burden of clinical documentation and free up providers' time. In the non-clinical domain, AI is being leveraged to automate administrative tasks such as medical record-keeping, billing, and patient scheduling, which are seen as "convoluted" and "ripe for disruption". Diagnostics and Personalisation: AI's data-processing capabilities are used to analyse vast datasets for earlier disease detection, more accurate diagnoses, and the creation of personalised treatment plans. Platforms that analyse medical imaging are positioned as tools that augment a clinician's ability to spot abnormalities and improve accuracy. The narrative behind these applications is straightforward: AI can perform tasks that are typically done by humans, but in less time and at a fraction of the cost.This message resonates strongly with hospital administrators, IT teams and payers, as it offers a clear path to cost savings and streamlined operations. However, this singular focus on efficiency leaves a significant gap in the market. It neglects the profound importance of trust, empathy, and the human connection that are central to the patient and clinician experience. While AI can improve patient experience by making care easier to find and schedule, the core story remains centred on output and cost reduction, creating an emotional and psychological opening for a contrarian narrative built on human-centric care. The Foundational Flaws and Inherent Vulnerabilities of the AI-First Model The Unproven Promises: Hype vs. Reality The intense hype surrounding AI in healthtech masks a harsh reality: a significant number of these projects are failing to deliver meaningful results. A recent MIT study found that a staggering 95% of generative AI business projects have failed to provide measurable productivity gains or revenue acceleration, despite the substantial investments they have attracted. This dramatic disconnect between market perception and real-world outcomes suggests that the sector may be facing a bubble reminiscent of the dot-com crash. The failures are not merely a result of poor execution; they are often rooted in fundamental technical and operational challenges. AI models in healthcare are highly dependent on high-quality data, but the industry's data is notoriously fragmented, unstructured, and lacks standardisation. Furthermore, training these models requires extensive data annotation, a time-consuming and expensive process that can only be performed by medical professionals. Even if a model performs well in one facility, it may fail in another due to differences in medical protocols and equipment, making the creation of universal solutions a complex endeavour. This high rate of failure and the difficult path to implementation are creating a form of "tech trauma" among healthcare providers, who may become increasingly risk-averse and skeptical of unproven technological claims. The Ethical and Regulatory Minefield Beyond technical challenges, the AI-first model is fraught with ethical and regulatory risks that are beginning to attract scrutiny. These are not mere side effects of the technology but fundamental vulnerabilities that cannot be easily mitigated. One of the most pressing concerns is data bias. AI models trained on flawed or historically biased datasets can perpetuate and even amplify systemic inequalities. Examples include a widely used risk prediction algorithm that underestimated the care needs of Black patients because it was trained to predict healthcare costs rather than illness severity. Similarly, AI systems trained predominantly on images of lighter skin tones are more likely to under-diagnose skin cancers in people with darker skin, a significant issue with broad implications for health equity. These examples illustrate that when AI is a core part of the solution, the risks of misdiagnosis, inappropriate treatments, or denied access to care are very real. Another major vulnerability is the "black box" problem. The decision-making process of many AI models is opaque, making it difficult for clinicians to understand how conclusions are reached. In a high-stakes clinical environment, this lack of transparency is a major barrier to adoption and trust, as it creates a lack of accountability if an AI makes a harmful decision. The legal and regulatory landscape is also struggling to keep pace, with frameworks like the EU AI Act emerging to impose strict requirements for fairness and transparency. A company that bases its value on a fragile, unproven AI foundation is entering a legal and ethical minefield that could lead to significant fines and reputational damage. The Human and Clinical Distrust The AI-first narrative often overlooks a critical stakeholder: the patient and the clinician. In a high-stakes industry like healthcare, the need for human connection, empathy, and trust is paramount. A recent study found that a majority of patients, 60%, are uncomfortable with a doctor relying on AI, and a third believe it could worsen their treatment. This skepticism is not unfounded; only 29% of people in a UK study would trust AI for basic health advice. The core value proposition of an AI-first company, which focuses on cost reduction and automation, is in direct conflict with the deeply personal and emotional nature of the patient-provider relationship. While AI can offer efficiency, it lacks the human touch and empathetic understanding that clinicians provide. When technology is presented as a replacement for human judgment and interaction, it can create a sense of unease and disconnect. This fundamental tension between a technology-centric narrative and the human need for care presents a clear strategic opening for a company that can credibly offer a different story—one that prioritizes and celebrates human involvement. The Contrarian Advantage: Building a "Non-AI Story" Defining a Contrarian Strategy in HealthTech A contrarian strategy is an investment or branding approach that "bucks against existing market trends" to find an opportunity in an opinion that is "unexpected or contrary to what is widely believed". In the context of healthtech, this means consciously moving against the current of AI-first narratives and venture capital flows. The goal is to create a "polar" brand association that sets a company "apart from all other competitors in a radical way" by highlighting the over-saturation and potential vulnerabilities of the consensus. This is a strategy of deliberate differentiation. When the market is saturated with the "same regurgitated narratives" about efficiency and automation, a company that offers a different, more compelling story is more likely to be heard and to expand its reach. The value in going against the consensus is that what you are saying gets "diluted and competed away" when you go with the crowd. The contrarian advantage is not about rejecting technology, but about refusing to make it the central character of the story. The central character must be the human problem being solved, with technology as a powerful, but supporting, force. Case Studies in Human-Centricity The viability of a "non-AI story" is not a theoretical concept; it is a proven business model demonstrated by successful companies that have built strong, defensible value propositions. These companies' success validates that investors and customers will back solutions that solve painful, specific problems, irrespective of whether they are AI-first. Calm: This company's success is rooted in its focus on mental well-being, stress, and sleep. Its value proposition is built on human-guided meditation, soundscapes, and expert-led programs. The brand is built around emotional connection and personal relief, providing a trusted source of support rather than a technological solution to a human problem. Maven Clinic: As a virtual clinic for women's and family health, Maven positions itself around specific patient populations and their unique needs. Its value proposition is "inclusive care access" and personalised support for families, with technology acting as the platform that enables these services.The story is about people helping people, using technology as a facilitator. Force Therapeutics: This platform for musculoskeletal conditions focuses on patient-provider communication and video-based education. Its value is in empowering patients and clinicians with tools that improve communication and care coordination, rather than a narrative of replacing human interaction with an algorithm. These companies demonstrate that a problem-first, human-centric approach can lead to a powerful, scalable business model. Their success proves that a "non-AI story" is not a defensive position but a potent strategic choice. The core of their message is a tangible human outcome, feeling better, having access to care, or a better care experience. The technology is an enabler, not the story itself, a crucial distinction that directly counters the prevailing AI funding trend. The Strategic Playbook for a Human-Centric HealthTech Business Crafting the Value Proposition: From Tech to Trust To build a successful contrarian brand, a company must shift its value proposition from a focus on technological features to one that is "human needs-driven" and sparks an "emotional connection". This requires a conscious effort to move beyond product-centric messaging, such as "our software is smarter and faster," and reframe it around a tangible, human-centric promise. For example, instead of claiming an AI solution "can interpret brain scans," a human-centric company would say, "our solution helps doctors find more bone fractures than humans can, reducing missed diagnoses and improving patient outcomes". The former is a technical claim, while the latter addresses a human problem and a human benefit. This reframing is not just about marketing; it is about fundamentally defining the business around the most critical, often overlooked, aspects of healthcare, trust and outcomes. A brand that leads with a story of reducing physician burnout so they can focus on patient care is more durable and emotionally resonant than one that simply touts automation and cost savings. Establishing Trust and Credibility: The New Competitive Moat In an industry where data breaches and ethical failures are constant threats, credibility is a powerful and defensible competitive moat. A "non-AI story" can be explicitly built around a company's commitment to trust and transparency. This requires a multi-pronged approach: Compliance and Transparency: A company must implement robust data protection policies from the outset, ensuring full compliance with complex regulations like HIPAA and GDPR. Non-compliance can result in massive fines and significant reputational damage. Demonstrating Expertise: Building authority is essential. This can be achieved through thought leadership via content marketing, such as publishing case studies and e-books, and leveraging partnerships with reputable organisations. Engagement and Delivery: A company must be proactive in listening to customer feedback and consistently delivering on its promises. This builds confidence and fosters long-term relationships, distinguishing the company from those that fail to deliver on over-hyped promises. The "AI Gold Rush" has created a low-trust environment due to ethical concerns, data bias, and a high failure rate of projects. The contrarian company, by contrast, can build its brand on the antithesis of these flaws: a focus on human oversight, proven outcomes, and a genuine commitment to ethical and responsible practices. This is not a technical feature but a fundamental business practice that becomes a core, difficult-to-replicate part of the "non-AI story." The "Human-in-the-Loop" Model: A Superior and More Mature Approach The most sophisticated healthtech business model is not "AI-first" but a "human-in-the-loop" model that strategically blends automation with human oversight. This approach directly addresses the primary flaws of an AI-only solution while retaining the benefits of efficiency. The philosophy behind this model is not to replace people, but to "evolve how people work". It uses technology to automate routine, repetitive tasks, such as administrative work, data gathering, or first-pass alert triage, while reserving critical, high-impact decisions for human experts. This hybrid model directly mitigates the risks inherent in "AI-first" solutions. The "black box" problem is addressed because a human is always in the loop to review and contextualise AI recommendations. The model adds the "empathetic understanding" that AI lacks and ensures accountability by making a human ultimately responsible for the decision. The strategic superiority of this approach is clear. It leverages AI's power to drive efficiency while mitigating the high risks of misdiagnosis, bias, and lack of accountability. This positions the company as a responsible and outcome-focused innovator, not a high-risk tech speculator. The "human-in-the-loop" model is a more mature and durable business strategy that is well-suited for a high-stakes industry where trust and safety are paramount. Strategic Pillars: AI-First vs. Human-Centric Models Strategic Dimension AI-First Model Human-Centric (Non-AI) Model Core Philosophy Technology as the solution. The human as the solution, technology as an enabler. Primary Value Driver Efficiency, cost reduction, and scale. Trust, safety, empathy, and improved outcomes. Primary Audience Hospital administrators, IT teams, payers. Clinicians and patients. Competitive Moat Technological innovation, data exclusivity. Seamless integration, human expertise, brand trust. Key Risks High failure rate, data bias, regulatory uncertainty, lack of trust. Perceived as "outdated," slower to attract investment. Investor Pitch "We are using advanced AI to transform healthcare." "We solve a specific, painful problem for people." Competitive Moats Beyond AI For a contrarian company, the ultimate defense is building moats that are not dependent on AI. As AI tools become increasingly commoditised, true differentiation will come from factors like "integration, distribution and documented workflows". A key vulnerability for many AI startups is their inability to integrate seamlessly with outdated legacy systems like EHRs. A "non-AI" company can build a powerful competitive advantage by focusing on creating solutions that "fit with people where they live, work, and receive care" and seamlessly integrate into existing systems and protocols. This is a more mature approach that recognises the operational complexities of the healthcare industry. Furthermore, a "non-AI" company can build a more sustainable business model by focusing on a "clear path to profitability" and a "durable return on investment". The high cost and lack of proven unit economics for many generative AI models pose a significant financial risk. By focusing on a problem with a demonstrable and sustainable business model, a contrarian company can position itself for long-term growth and profitability, while overfunded, undifferentiated AI-first companies risk becoming superfluous or contributing to a bubble.The strategic choice to be a "non-AI" company is not a regression to "outdated technology" but a sophisticated focus on the foundational aspects of business health. Conclusion: A Nuanced Path to Sustainable Value The healthtech industry is at a pivotal juncture. While the "AI-first" narrative has captured the imagination of investors and the media, its foundations are more fragile than the hype suggests. The high failure rate of generative AI projects, combined with the significant ethical, regulatory, and trust-based vulnerabilities, presents a compelling opportunity for a contrarian strategy. A successful healthtech company of the future will be one that embraces a "non-AI story" not as a compromise, but as a strategic advantage. This is a sophisticated choice to lead with a problem-first, human-centric value proposition, to build a brand around trust and transparency, and to establish competitive moats in seamless integration and superior distribution rather than in technology alone. This approach is not a rejection of progress, but a recognition that technology, including AI, is most powerful when it is a thoughtfully integrated tool in service of a human-first mission. The ultimate contrarian move is to bet on the enduring value of trust and proven outcomes in a market intoxicated by hype. Nelson Advisors > HealthTech and MedTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Strategic HealthTech Buyers Going Global: A New Era of Cross-Border M&A Executive Summary The global HealthTech landscape is undergoing a profound structural transformation. A confluence of economic headwinds in mature markets, particularly in North America and a recalibration of investor sentiment away from speculative growth has positioned cross-border mergers and acquisitions (M&A) as the primary engine of strategic growth and liquidity. This report presents a detailed analysis of this new paradigm, arguing that strategic buyers, from big Pharma and health systems to private equity firms, are leveraging M&A to acquire disruptive technologies, access new patient populations and consolidate market share. This shift is not merely cyclical; it represents a fundamental maturation of the sector, where M&A has supplanted the initial public offering (IPO) as the dominant exit strategy. The analysis will reveal that while deal volume and values are on the rise, success is contingent on navigating a complex web of regulatory, cultural and operational challenges inherent in global transactions. The report concludes with a strategic blueprint for both acquirers and startups to capitalise on this trend, emphasising that the future of HealthTech is global and its success will be defined by the skill and foresight of market participants. The Catalysts for a Global Shift in HealthTech M&A The current surge in cross-border HealthTech M&A is not an isolated event but rather the logical outcome of a series of market corrections and strategic recalibrations that have unfolded since the peak of the pandemic. This section establishes the foundational economic and market conditions that have driven a fundamental shift in investment and exit strategies. The Post-Pandemic Correction: Slower Domestic Growth and Investor Re-evaluation The COVID-19 pandemic acted as a powerful accelerant for the HealthTech industry, with the sector experiencing what many referred to as a "10-year growth in 10 months". This period saw a massive influx of capital, with HealthTech funding surging from $16 Billion in 2020 to an unprecedented $62.5 Billion in 2021.This funding boom, however, created an overheated market where valuations often became disconnected from operational fundamentals, fueled by a "growth-at-all-costs" mindset. The market began to rebalance in 2022 and 2023. A combination of persistent inflation, elevated interest rates, global geopolitical events and supply chain disruptions introduced significant uncertainty. This turbulence caused a sharp drop in investment activity and a significant contraction in valuations, with the inflated figures of 2021 continuing to "loom over the market". Simultaneously, the public market became increasingly volatile, effectively closing the IPO window for many HealthTech startups. In response, investors and venture capital firms began to shift their strategies. The new focus was not on speculative growth but on companies with "strong operational and financial fundamentals" and a clear path to profitability. This change in priorities signalled a move from higher-volume, smaller funding rounds in early-stage entities toward fewer, larger investments in more mature, expansion-stage organisations with proven business models. This created a bifurcated market where weaker players, unable to achieve profitability, were left exposed and susceptible to acquisition at distressed valuations, while high-quality businesses with novel solutions continued to attract capital. The Rise of M&A as the Dominant Liquidity Mechanism As the IPO market ceased to function as a reliable exit avenue, M&A emerged as the primary mechanism for liquidity and consolidation. This trend is not merely anecdotal; it is quantified by a demonstrable rebound in deal volume and value. In the first half of 2025, there were 277 M&A deals in the HealthTech sector, placing the market on a trajectory to surpass the 467 total deals of 2024. Similarly, disclosed deal values were on a growth path, reaching $10.3 Billion in the first half of 2025 and on pace to exceed the 2024 total of $19.2 Billion. This activity has provided a welcome relief for venture investors, as M&A values in 2025 have surpassed previous peaks, signalling a more confident deal-making environment. This M&A surge is driven by a combination of factors, including strategic consolidation within the healthcare industry, rapid technological advancements, evolving regulatory landscapes, and a significant amount of "dry powder" from private equity firms looking to deploy capital. The transition from IPOs to M&A as the dominant exit strategy marks a profound structural shift, signifying a fundamental maturation of the market. IPOs are typically reserved for high-multiple, high-risk growth stories, while M&A, particularly by strategic and financial buyers, is more focused on tangible synergies, proven revenue streams and the consolidation of fragmented markets. This indicates that the HealthTech ecosystem is moving away from being a collection of disparate "point solutions" and is consolidating into integrated, scalable platforms. As a result, startups are now incentivised to build for an M&A exit from inception, with a focus on profitability, operational efficiency, and seamless integration, rather than simply on user growth. The Global Context: Disparate Market Maturity and the Search for Growth While the North American market has experienced a significant slowdown, the global landscape presents a more complex picture. Deal-making activity is not uniform across continents; rather, it is characterised by disparate stages of market maturity. Europe, for example, saw a resurgence in digital health funding in 2024, reaching $3.5 Billion, a 19% year-over-year increase in the third quarter alone. This trend, particularly pronounced in the UK, Germany, and France, reflects a renewed investor confidence in the region. Similarly, M&A activity in Asia rebounded in 2024, with the region recording the most insurance mergers and acquisitions globally.This was driven in part by regulatory changes in India that facilitated increased foreign investment. Africa also saw a significant rise in both deal volume and value, with a 468% increase in deal value from 2023 to 2024. This global rebalancing suggests that acquirers, particularly those from mature domestic markets, are increasingly looking to tap into more dynamic or less saturated regions. For large corporations facing slower growth at home, cross-border M&A provides a direct and efficient pathway to new customer bases, diverse revenue streams, and fresh opportunities for growth. The Strategic Rationale: Why Corporates are Going Global The decision by strategic buyers to pursue cross-border M&A is driven by a clear set of strategic imperatives that extend beyond simple financial consolidation. This section explores the core motivations compelling large corporations to seek acquisitions beyond their home markets. Accessing Disruptive Technology and Talent: The AI Imperative A primary driver for cross-border acquisitions is the desire to acquire disruptive technology and proprietary intellectual property. Strategic buyers are not merely seeking to expand their portfolios; they are looking to gain a competitive edge by integrating innovative solutions that can fundamentally transform healthcare delivery and patient outcomes. Artificial intelligence (AI) is at the forefront of this trend. Acquirers are no longer merely experimenting with AI; they are actively acquiring companies with "proven, working technology" to accelerate their own capabilities. Examples of this include Tempus AI's acquisition of digital pathology leader Paige, a deal focused on leveraging AI for precision medicine. Similarly, the increasing venture capital channeled into AI-native companies like Ambience Healthcare and Carlsmed suggests that these clinical AI platforms are becoming a prime class for future M&A targets. Beyond technology, these deals are also a direct route to acquiring valuable talent and expertise. HealthTech startups often attract and retain highly skilled professionals with the knowledge and passion to create impactful solutions. By acquiring these companies, larger firms can quickly access a new talent pool, enhance their R&D capabilities, and foster a culture of innovation that may be difficult to cultivate internally. Geographic Market Expansion and Risk Diversification Expanding into new geographic markets is a key driver of cross-border M&A. Acquiring an overseas company provides a strategic shortcut to a broader customer base, allowing buyers to bypass the significant time and cost involved in building a local presence from the ground up. This approach helps mitigate over-dependence on a single domestic market and diversifies revenue streams, offsetting the risks of economic downturns, regulatory shifts, or political instability in any one country. A notable example of this strategy is Teladoc Health's acquisition of Telecare, an Australian company specialising in virtual healthcare delivery. The motivation for this acquisition was explicitly to strengthen Teladoc Health's presence in the Australian market and expand its international footprint. Securing Category Leadership and Filling "Patent Cliff" Gaps Large pharmaceutical and medtech companies are actively using M&A to secure category leadership and optimise their portfolios. The "string of pearls" strategy is particularly prevalent, where large players acquire a series of smaller, innovative companies to fill pipeline gaps, enhance their core platforms, and hedge against the financial risks posed by upcoming patent cliffs. This trend is most evident in the biopharmaceutical sector, where companies are targeting innovative late-stage biotech firms to reposition their portfolios for growth. High-value transactions like Novo Holdings' acquisition of Catalent and Sanofi's acquisition of Blueprint Medicines are examples of this strategic approach, aimed at securing growth pipelines in high-demand therapeutic areas such as oncology, rare diseases, and immunology. For traditional healthcare incumbents, M&A is becoming a critical tool to counter not just financial volatility, but fundamental shifts in the healthcare value chain. As new delivery models emerge, these companies are leveraging M&A to fast-track their digital transformation, gaining efficiencies and expanding their capabilities beyond traditional business models. This represents a broader industry-wide re-platforming, where the core business is no longer just drug discovery or hospital management but also includes leveraging data, AI, and patient engagement platforms to improve outcomes and reduce costs. High Demand HealthTech Segments and Premium Valuations The flight to quality in the HealthTech market has led to a clear bifurcation, with certain sub sectors and technological capabilities commanding premium valuations. This section details the specific segments that are most attractive to strategic and financial buyers and the financial metrics driving acquisition decisions. The Primacy of AI and Advanced Analytics Artificial intelligence is a dominant force in HealthTech M&A, driving the highest valuations in the market. Acquirers are paying a premium for companies with proprietary AI algorithms, especially in areas like diagnostics, drug discovery, and predictive analytics. The strategic rationale is clear: AI-native platforms offer a competitive edge by improving patient care, enhancing diagnostics, and increasing operational efficiency.The acquisition of Paige, an AI company specialising in digital pathology, by Tempus AI, a technology firm focused on precision medicine, exemplifies this trend. Advanced data analytics providers are also hot M&A targets due to the critical need for secure, interoperable data platforms in a consolidating market. Datavant's acquisition of Ontellus, a provider of health records retrieval, was driven by the objective of creating an integrated platform to securely connect health records to those who need them. This focus on data-driven capabilities is paramount for strategic buyers who are modernising their operations and seeking to comply with complex regulatory requirements. Digital Therapeutics, Telehealth and Patient-Centric Platforms The post-pandemic telehealth boom has matured, leading to a new generation of hybrid health platforms that combine virtual and in-person care. While the direct-to-consumer market has faced challenges, the business-to-business (B2B) segment remains strong as established players seek to protect their market position and develop their digital offerings. This has resulted in a wave of consolidation. Notable examples include the acquisition of Livongo by Teladoc Health, a deal driven by the complementary nature of their offerings and a shared mission to empower patients. The merger of EVERSANA and Waltz Health is another instance of companies consolidating to create unified platforms that redefine pharmaceutical commercialisation and patient access. These deals reflect the broader industry shift from fragmented point solutions to scaled, integrated platforms that provide a comprehensive continuum of care. The Consolidation of Health Systems and Healthcare Services The healthcare services sector is experiencing a significant surge in consolidation, often driven by financial distress. The post-pandemic reality check has left many startups, fueled by cheap capital and telehealth hype, struggling to achieve profitability. This has turbo-charged distressed M&A activity, with deals involving distressed parties rising significantly. Strategic buyers, including private equity (PE) firms and larger healthcare organisations, are capitalising on this buyer's market to acquire weakened firms at "bargain-basement valuations". This trend is not isolated to the US; it is also reshaping the UK HealthTech ecosystem, concentrating power in fewer, stronger hands. The merger of hospital systems like Northwell Health and Nuvance Health illustrates the push for streamlined workflows, reduced redundancies and the creation of larger, more efficient healthcare platforms. Key Financial Metrics Driving Acquisition Decisions The M&A market in 2025 is defined by a "flight to quality," where companies with strong fundamentals are highly sought after. Buyers are paying a premium for specific attributes that promise future growth and efficiency gains. These include high gross margins, a high percentage of recurring revenue from subscriptions or long-term contracts, and established intellectual property (IP) portfolios. The average enterprise value (EV) to revenue multiple for most HealthTech companies is between 4-6x ARR . However, those companies with proprietary AI algorithms and advanced analytics capabilities are commanding premium valuations, often reaching 6-8x ARR or more. For companies with positive earnings, the EV to EBITDA multiples have seen a slight increase from 2024, ranging from 10-14x, reflecting a cautious optimism in the market. This focus on profitability and proven business models underscores a new reality for startups: the ultimate value of their company will be determined not by their speculative growth story, but by their ability to demonstrate tangible, repeatable value for an acquirer. Global M&A in Action: Case Studies and Regional Flows The trends and strategic rationales discussed are exemplified by a series of high-value cross-border transactions that have defined the market in 2024 and 2025. This section provides a detailed overview of these notable deals, highlighting the key players and their motivations, and also examines the pivotal role of private equity. Cross-Continental Deal Highlights The globalisation of HealthTech M&A is evident in recent deals that span continents, driven by the strategic motives of both traditional and non-traditional acquirers. Johnson & Johnson (US) and Numab Therapeutics (Switzerland): In a deal announced in May 2024, Johnson & Johnson acquired Numab Therapeutics for $1.25 billion in cash. The primary driver for this transaction was the acquisition of Numab's lead asset, an IL-4Ra antagonist for atopic dermatitis, which strengthens J&J's drug development pipeline in a key therapeutic area. This exemplifies the "string of pearls" strategy, where large pharmaceutical players acquire innovative, late-stage biotech companies to fill pipeline gaps. AstraZeneca (UK) and Amolyt Pharma (France): In March 2024, AstraZeneca announced its acquisition of France-based Amolyt Pharma for an upfront payment of $800 Million and a contingent payment of up to $250 million. This cross-border deal was motivated by AstraZeneca's desire to secure a promising parathyroid hormone receptor 1 agonist for hypoparathyroidism, further expanding its portfolio in rare diseases. Teladoc Health (US) and Telecare (Australia): Teladoc Health acquired Australian-based Telecare, a technology-enabled company specialising in virtual healthcare delivery. This acquisition, while smaller in scale, demonstrates the strategic imperative of geographic market expansion. Teladoc Health's motivation was to strengthen its presence in the Australian market and extend its service area. New Mountain Capital (US) and Access Healthcare (India): New Mountain Capital acquired a majority stake in Access Healthcare, an Indian revenue cycle management (RCM) group, for $2 Billion. This transaction highlights the increasing cross-border interest from private equity firms in services-based businesses with proven profitability and scalability, particularly those that can service the US market from a lower-cost location. The Role of Private Equity and Financial Acquirers Private equity firms are playing a progressively larger role in the HealthTech M&A market. With a significant amount of "dry powder" and the anticipation of falling interest rates, PE firms are actively seeking opportunities to deploy capital. They are capitalising on the buyer's market by snagging innovative tech at cut rates through distressed M&A, as well as pursuing "buy-and-build" strategies in highly fragmented verticals like behavioural health and medical devices. Examples of PE activity include Clearlake Capital's $5.3 Billion acquisition of ModMed and Bain Capital's $2.6 billion acquisition of HealthEdge. The globalisation of HealthTech M&A is not just a US-outward phenomenon; it is a multi-directional flow with new regional hubs emerging as both buyers and sellers. While US companies dominate M&A activity, with 60% of acquirers and 80% of targets based there, the data shows increasing activity from European and Asian firms. The renewed investor confidence in Europe and the increased deal volume in Asia suggest that the pool of potential acquirers is expanding, creating more opportunities for exits for startups globally. This new dynamic adds complexity for dealmakers who must now navigate a wider range of regulatory, cultural, and valuation standards. Notable Cross-Border HealthTech M&A Transactions (2024-2025) Acquirer Target Target Country Deal Value Deal Date Primary Motivation Johnson & Johnson Numab Therapeutics Switzerland $1.25 billion May 2024 Access to IP, Pipeline Expansion AstraZeneca Amolyt Pharma France Up to $1.05 billion March 2024 Pipeline Expansion, IP Acquisition Teladoc Health Telecare Australia Not disclosed August 2025 Geographic Market Expansion New Mountain Capital Access Healthcare India $2 billion H1 2025 PE Roll-Up, Access to Services & Talent KKR & Co. Cotiviti (50% stake) US Not disclosed February 2024 Financial Investment, Data & Tech Novartis Calypso Netherlands Up to $425 million January 2024 Portfolio Expansion AbbVie OSE Immunotherapeutics France Not disclosed March 2024 Partnership, R&D Collaboration Boehringer Ingelheim Ochre Bio UK Not disclosed October 2024 Partnership, R&D Collaboration HealthTech Sector Valuation Multiples by Sub-Category (2025) Sub-Sector Typical Revenue Multiple (EV/ARR) Typical EBITDA Multiple (EV/EBITDA) Key Drivers AI and Analytics x6-8+ x12-16+ Proprietary algorithms, proven tech, IP, efficiency gains RCM (Revenue Cycle Management) x4-6 x10-14 Operational efficiency, cost reduction, recurring revenue Digital Therapeutics x4-6 x10-14 Patient-centric platforms, B2B models, scalability Telehealth x4-6 x10-14 B2B solutions, hybrid care models, market consolidation General HealthTech x4-6 x10-14 Strong fundamentals, high gross margins, recurring revenue Overcoming the Hurdles of Cross-Border Integration While the strategic rationale for global HealthTech M&A is compelling, the success of these transactions is ultimately determined by an acquirer's ability to navigate a complex web of non-financial hurdles. The primary value of a cross-border deal lies not just in the asset being acquired, but in the acquirer's capability to effectively integrate and scale a culturally and regulatory-foreign entity. Navigating a Fragmented Regulatory and Compliance Landscape The global regulatory environment for HealthTech is a complex and fragmented maze. Regulators, whose procedures are often geared toward more conventional applications, face a significant challenge in keeping pace with the rapid innovation in digital health. Different jurisdictions have wildly varying standards, from the FDA's approach to Software as a Medical Device (SaMD) in the U.S. to the European Union's CE markings and the General Data Protection Regulation (GDPR). A key challenge for acquirers is ensuring that the target company has a "proven track record of navigating complex regulatory environments," as this reduces risk and speeds up integration. Data privacy and cybersecurity present a paramount concern. Laws such as HIPAA in the U.S., the California Consumer Privacy Act (CCPA), and Europe's GDPR introduce a multitude of varying requirements for handling sensitive patient information. A merger of incompatible IT systems can leave critical security gaps that are ripe for exploitation by hackers.Due diligence in this area is more challenging across borders due to differences in language, accounting standards, and disclosure norms, which can obscure critical issues.Furthermore, geopolitical and trade policy risks, such as potential tariffs or increased scrutiny on foreign investments in strategic industries, are now being factored into due diligence and deal valuation. The Critical Challenge of Cultural and Operational Integration Cultural discord is a leading cause of deal failure. When ignored, differences in communication styles, leadership approaches, and organisational values can lead to a variety of unanticipated consequences, including low employee morale, high turnover, and even patient safety risks. These risks are significantly heightened when traditional healthcare organisations, such as hospitals or pharmaceutical firms, merge with "nontraditional players" like tech startups. The cultural gap between a hierarchical, risk-averse health system and a lean, agile tech startup can be immense, leading to a clash of priorities and working styles. Operational integration, including the merging of IT infrastructure, business processes, and HR systems, requires meticulous planning to avoid delays and inefficiencies. Without a clear roadmap, the very synergies a deal was meant to achieve can be diminished or even destroyed. The value proposition of a deal is often undermined by these non-financial hurdles, which highlights that the M&A process in HealthTech is fundamentally different from other sectors. The highly regulated nature, patient safety concerns, and sensitive data require an integration strategy that goes beyond simple cost-cutting and focuses on achieving deep, mission-aligned, and compliant operational harmony. Strategic Recommendations and Forward Outlook The market correction has set the stage for a new, more sustainable era of HealthTech development driven by M&A. The trend of cross-border deals will accelerate as corporations continue to seek innovative solutions, market expansion, and portfolio optimisation. Success in this environment will be defined by strategic execution and a nuanced understanding of the global landscape. A Blueprint for Strategic Buyers: Due Diligence, Integration and Value Realisation To maximise the value of a cross-border HealthTech acquisition, strategic buyers should adopt a multi-layered approach to due diligence and post-merger integration. Pre-Acquisition: Conduct multi-layered due diligence that extends beyond financial statements to thoroughly assess the target's regulatory compliance, intellectual property, and cultural alignment. Prioritise companies with a "proven track record" in navigating the regulatory environments of their home markets. During Negotiation: Consider deal structures that retain key management and allow the acquired entity to operate as an independent subsidiary for a defined period. This approach can ease the cultural transition and prevent the loss of critical talent and institutional knowledge. Post-Merger Integration: Implement a clear and consistent communication plan to address employee anxieties and build trust. Conduct proactive cultural assessments and provide cross-cultural training to help bridge differences in communication and work styles. Focus on a phased integration of IT and operational systems to avoid security vulnerabilities and operational disruption, particularly when merging incompatible data platforms. Positioning for an Exit: A Guide for HealthTech Startups In this new M&A-driven market, HealthTech startups should reorient their strategies to become attractive acquisition targets. Focus on building a business with "strong operational and financial fundamentals" and a "proven business model" rather than on achieving rapid, unfettered growth. Develop solutions with clear value propositions and a tangible return on investment for strategic buyers, such as demonstrable cost savings or efficiency gains. Proactively manage and document intellectual property, regulatory compliance, and data security from day one to create a "competitive moat" and reduce risk for potential acquirers. A HIPAA-compliant platform with FDA clearances, for example, is inherently more valuable than one without. Consider M&A as a primary exit strategy and structure the company to be an attractive target, not just an IPO candidate. This involves building a strong, cohesive team that can be integrated successfully into a larger organisation. Concluding Outlook: A New Era of HealthTech Globalisation The global HealthTech market has moved from an era of speculative exuberance to a period of pragmatic consolidation. Slower domestic growth in mature markets, combined with a re-evaluation of investment priorities, has made cross-border M&A the most viable path forward for both corporations seeking growth and startups seeking an exit. The future of HealthTech is global and consolidated, but its success will be defined not by the sheer size of the deals, but by the skill and foresight of acquirers in navigating the complex regulatory, cultural, and operational challenges that lie beyond their borders. This is a period of immense opportunity for those prepared to act strategically and with a nuanced understanding of the new global landscape. Nelson Advisors > HealthTech and MedTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide #Divestitures   #Corporate   #Portfolio   #Optimisation   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us @ HealthTech events   Digital Health Rewired > 18-19th March 2025 > Birmingham, UK  NHS ConfedExpo   >  11-12th June 2025 > Manchester, UK  HLTH Europe >  16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate >  25th June 2025, London, UK  HIMSS AI in Healthcare  >  10-11th July 2025, New York, USA Bits & Pretzels >  29th Sept-1st Oct 2025, Munich, Germany   World Health Summit 2025  >  October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit >  October 16th 2025, London, UK  HLTH USA 2025 >  October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 >  10th-13th November 2025, Lisbon, Portugal   MEDICA 2025 >  November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk

Nelson Advisors: Boutique European HealthTech Investment Banking Firm Nelson Advisors: Boutique European HealthTech Investment Banking Firm This report provides a detailed analysis of Nelson Advisors, a highly specialised mergers and acquisitions (M&A), partnerships and investment advisory firm. The firm is exclusively dedicated to the dynamic European healthcare technology (HealthTech) sector, with an extended reach into the UK and North America. The analysis reveals that the firm's primary competitive advantage is rooted in its unique "Founders for Founders" approach, which is underpinned by the direct entrepreneurial experience of its leadership. This model enables a nuanced understanding of the HealthTech ecosystem that distinguishes Nelson Advisors from larger, generalist investment banks and M&A advisory firms. The firm's value proposition is built on a dual foundation: the deep, hands-on entrepreneurial background of its founding partner Lloyd Price and the extensive, multi-billion-dollar global M&A expertise of co-founder Paul Hemings. This combination allows Nelson Advisors to provide a sophisticated yet deeply empathetic advisory service. The firm is strategically positioned at the forefront of critical, high-growth sub-sectors such as Healthcare AI and Cybersecurity, and it is particularly focused on guiding early-stage companies through M&A exits. This focus is a direct and intelligent response to current market conditions, including a tighter venture capital funding environment and a less active initial public offering (IPO) market. Overall, Nelson Advisors’ leadership position is not derived from M&A volume or value across all sectors, but rather from its deep, qualitative specialisation and its thought leadership in its dedicated niche. Defining Nelson Advisors: The European HealthTech Specialist Nelson Advisors is a highly specialised advisory firm with a singular focus on the healthcare technology sector. It is precisely defined as a mergers and acquisitions, partnerships and investment advisory firm that operates within the dynamic and rapidly evolving HealthTech landscape. This exclusive dedication to a specific industry is the bedrock of the firm's value proposition, providing a nuanced understanding of the unique market dynamics and technological advancements that are essential for successful transactions in this complex field. The firm's primary physical presence is in London, UK, positioning it strategically within the European HealthTech hub. While its physical headquarters are in Europe, its geographic scope is deliberately broad, catering to a client base that spans the UK, Europe, and North America. The international capabilities of its partners are extensive, with corporate finance experience and transaction exposure across numerous countries, including the US, Ireland, Sweden, Denmark, Switzerland, Germany, Austria, Italy, Poland, Ukraine, Russia, Kazakhstan, Hong Kong, Singapore, and Australia. This international reach allows the firm to facilitate complex, cross-border transactions that are increasingly common in the global HealthTech market. Exclusive Specialisation in the HealthTech Ecosystem The core of Nelson Advisors' business model is its deep and exclusive specialisation in the HealthTech sector. This focus is a significant competitive advantage over generalist firms, enabling the firm to develop a sophisticated understanding of the industry's complex dynamics. The firm’s expertise extends across a diverse range of sub-sectors, which demonstrates a comprehensive grasp of the entire HealthTech ecosystem. The firm’s specialised sub-segments include: Digital Health: This area covers a broad range of technology-driven solutions, including mobile health apps, telehealth platforms, wearable devices, and personalized wellness solutions. HealthTech: The firm’s focus here is on fundamental technological innovations in healthcare, such as advanced medical devices, robotics, bioprinting, and nanotechnology. These are often associated with early-stage companies and startups developing novel solutions to healthcare challenges. Health IT: This specialisation centres on the technology used to manage, store, and share health information, including systems like electronic health records (EHRs) and clinical decision support tools. Consumer Health: The firm advises companies that provide solutions directly to the end user, including AI-driven diagnostics and digital biomarkers. Healthcare Cybersecurity: This is a crucial area of specialisation dedicated to ensuring the confidentiality, integrity, and availability of sensitive healthcare information and systems. The firm's focus on this segment is a direct response to the sensitive nature of patient data and the increasing sophistication of cyber threats. Healthcare AI: This sub-sector leverages AI techniques like machine learning and natural language processing to analyse complex medical data, provide insights, and enhance operational efficiency. The firm's explicit inclusion of Healthcare AI and Cybersecurity is not just a listing of services but a strategic signal of long-term foresight. The partners understand that these specific, complex, and high-growth areas will be central to future value creation and risk management in HealthTech. The firm's proactive specialisation in these sub-sectors, which are subject to emerging regulations like the EU AI Act and the European Health Data Space (EHDS), distinguishes them from firms with a more general HealthTech focus. This expertise is invaluable for clients who need to navigate advanced technological landscapes and stringent regulatory environments. Comprehensive M&A and Advisory Services Nelson Advisors offers a comprehensive suite of advisory services that are meticulously tailored to address the diverse needs of its clients. The firm provides a full range of M&A services, including both buy-side and sell-side advisory. For companies seeking to divest, the firm guides them through the intricate sell-side process, which includes valuation, market positioning, negotiation, and deal closure, with the goal of securing optimal outcomes for the seller. On the buy-side, Nelson Advisors assists clients in identifying, evaluating, and ultimately acquiring suitable HealthTech companies that align with their strategic objectives and growth mandates. Beyond traditional M&A, the firm's services extend to corporate divestitures, strategic partnerships, and portfolio optimization. The firm helps clients sell non-core assets or business units to liberate capital for reinvestment in higher-growth areas. The firm also provides investment-related advisory services, such as fundraising and commercial due diligence, demonstrating a role that goes beyond transactional execution to include strategic capital planning and partnership formation. A unique service offering is Tech Asset Sales, where the firm facilitates the sale of discrete technology assets, acknowledging the value of intellectual property and specific technological components that companies may wish to monetise or divest. Strategic Emphasis on Early-Stage Exits and Market Context A key aspect of the firm’s M&A services is its specific focus on Seed/Series A exits for early-stage companies.This is a highly strategic and market-responsive service. The firm acknowledges the increasing trend for early-stage HealthTech companies to find M&A as a primary exit route. This trend is driven by a tighter venture capital funding environment and a less active IPO market, making such exits a necessary outcome rather than an optional path. The firm's expertise and network are particularly valuable for these clients, as they can efficiently navigate the complex process of finding a strategic buyer and maximising value in a challenging capital market environment. Nelson Advisors also positions itself as a thought leader in the industry, evidenced by its publication of a market report on the European HealthTech M&A landscape. This report provides valuable context, noting a "cautious yet discernible rebound" in 2025 characterised by a "flight to quality," where deal values are increasing despite a decline in the number of transactions. The report attributes this to substantial private equity "dry powder" and the transformative influence of emerging technologies, particularly Artificial Intelligence. This publication reinforces the firm's expertise and credibility, positioning it as an authority in its field. Leadership, Expertise, and the "Founders for Founders" Approach Founding Partners' Professional Biographies Nelson Advisors' leadership is comprised of two founding partners, Lloyd Price and Paul Hemings, whose combined professional backgrounds represent a unique, dual-faceted expertise. This complementary skill set is the cornerstone of the firm's credibility and a significant competitive differentiator. Lloyd Price, a Partner and Co-Founder, brings more than 12 years of hands-on entrepreneurial experience as a successful HealthTech founder. He founded and successfully exited several companies, including Zesty in 2020, which was sold to a FTSE-listed company. Prior to his HealthTech career, he held senior roles in business development, marketing, and strategy at major technology firms like Yahoo! Europe and Badoo/Bumble. He is also actively involved in the ecosystem as a Health Executive in Residence at the UCL Global Business School for Health and as a judge for industry awards. Paul Hemings, also a Partner and Co-Founder, offers a decade of global M&A and capital raising expertise, complementing Price’s entrepreneurial background. He previously worked in senior investment banking advisory roles at Credit Suisse, where his transaction experience included over $50 billion in M&A deals and $40 billion in equity/financing transactions across a wide range of countries. Paul also has entrepreneurial experience, having founded and exited two early-stage companies, most recently in metabolic HealthTech. His educational background includes an MBA from the London Business School and an honors degree in Economics from Queen’s University in Canada. The collective expertise of the founders forms a powerful combination: the deep, operational knowledge of a successful founder and the extensive, high-level corporate finance perspective of a seasoned investment banker. This unique blend allows the firm to offer a highly strategic and comprehensive advisory service. The "Founders for Founders" Value Proposition The firm’s distinct "Founders for Founders" approach is central to its brand and market positioning. This model is not just a marketing slogan; it is a fundamental aspect of how the firm operates. The founding partners have personally "built, pivoted and scaled HealthTech businesses," and this firsthand entrepreneurial experience provides a profound and empathetic understanding of the HealthTech ecosystem. For clients, this approach translates into a unique advisory experience. The partners have walked in their clients’ shoes, enduring the challenges of securing funding, navigating market shifts, and ultimately pursuing a successful exit. This shared experience fosters a level of trust and strategic alignment that is difficult for generalist advisory firms to replicate. The advisors can offer guidance that goes beyond financial metrics to encompass the operational, psychological, and strategic complexities of the founder's journey. This deep, client-centric understanding is a key psychological and strategic differentiator, allowing Nelson Advisors to provide tailored solutions that a traditional banker might overlook because they lack this personal, lived experience. Market Positioning and Competitive Landscape Differentiation from Generalist M&A Firms and Investment Banks Nelson Advisors' market positioning is defined by its strategic choice to compete on depth of specialization rather than on sheer scale or volume. The firm’s status as "one of Europe's leading" M&A advisory firms is derived from its deep niche expertise, not from being a top-tier generalist ranked by overall M&A volume or value. Major global and European M&A players, such as Goldman Sachs, PwC, Rothschild & Co, UBS, and Houlihan Lokey, are frequently found in league tables based on total deal value or volume across all industries. Nelson Advisors is not typically found among these top-tier generalist advisors. This is not an indication of a lack of success; rather, it is a deliberate competitive strategy. By carving out a defensible and highly valuable niche in HealthTech, Nelson Advisors avoids direct competition with these giants on their home turf. The firm's "granular understanding" and "tailored approach" provide a distinct competitive advantage over generalist firms, who may have to hire outside experts or rely on broad knowledge bases when navigating the complexities of the HealthTech sector. This nuanced leadership is a qualitative advantage that distinguishes it from a purely quantitative, volume-based leadership model. Broader Market Context and Strategic Alignment The firm's strategy is perfectly aligned with the prevailing dynamics of the European HealthTech M&A market. The firm’s own market report provides a macro-level view, indicating a "cautious yet discernible rebound" in 2025. This resurgence is driven by improving macroeconomic conditions, significant private equity dry powder, and a strategic imperative for digital transformation across the healthcare ecosystem. The market is characterised by a "flight to quality," where increasing deal values are observed despite a decline in deal counts. This trend directly benefits a firm with Nelson Advisors' deep specialisation, as it can accurately identify and value high-quality assets for its clients. The availability of substantial private equity capital creates a strong demand side for the firm’s sell-side mandates. Furthermore, Nelson Advisors’ focused expertise in AI and Cybersecurity is a direct response to the "transformative impact of emerging technologies".This positioning makes them an ideal partner for the companies that are driving this market transformation, which must also navigate the specific complexities of the regulatory landscape. The firm is not merely a participant in the market; its strategy is an intelligent and deliberate response to its most critical dynamics. Sophisticated and highly specialised boutique investment banking firm The analysis of Nelson Advisors reveals a sophisticated and highly specialised boutique investment banking firm whose value proposition is built on a unique confluence of expertise. The firm's exclusive focus on the European HealthTech sector is a powerful competitive differentiator, allowing it to provide a level of nuanced, industry-specific advisory that generalist firms cannot match. The "Founders for Founders" approach, which is the cornerstone of its identity, is a strategic asset that provides a deeper, more empathetic understanding of client needs. This model, combined with the complementary entrepreneurial and corporate finance backgrounds of its founding partners, positions the firm as a trusted advisor capable of navigating the complex landscapes of M&A, partnerships, and investment advisory. Nelson Advisors’ strategic alignment with current market trends is evident in its focus on high-growth sub-sectors like AI and Cybersecurity, and its specialization in early-stage M&A exits. This approach demonstrates a forward-thinking business model designed to thrive in a market characterized by a "flight to quality" and shifting capital dynamics. While the firm's advisory track record is not publicly disclosed, the credibility of its leadership is built on a verifiable history of founding and successfully exiting multiple HealthTech companies. This expertise, combined with its thought leadership through published market reports, solidifies its standing as a leading authority within its specialised niche. For professional audiences, it is essential to recognize these distinctions and to understand that the firm's leadership is a qualitative one, based on the depth of its expertise, rather than a quantitative one based on broad market share. Nelson Advisors > Healthcare Technology M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

Nelson Advisors' Role in UK Market Entry Strategies Executive Summary This report provides a comprehensive analysis of Nelson Advisors LLP, a highly specialised London-based M&A and corporate advisory firm, and its strategic role in assisting healthcare technology (HealthTech) and MedTech companies with UK market entry. A central finding is the firm's use of a "Build, Buy, Partner, Sell" framework, which transcends traditional transactional advisory. This holistic model guides clients, particularly Western European and North American companies, through the full spectrum of strategic options for expanding into the UK, including M&A, strategic partnerships, or organic growth. The firm's deep expertise in high-growth sub-sectors like Healthcare AI and Cybersecurity is particularly relevant, allowing it to navigate a complex and stringent regulatory environment shaped by initiatives such as the EU AI Act and the European Health Data Space (EHDS). The credibility of Nelson Advisors LLP is further solidified by the synergistic backgrounds of its co-founders, who combine firsthand entrepreneurial experience with extensive global corporate finance expertise, and by the firm's proactive engagement in thought leadership. In a market characterised by a "flight to quality" and a challenging venture capital landscape, Nelson Advisors LLP is positioned as a pragmatic and indispensable partner for companies seeking to maximise shareholder value and achieve sustainable success in the UK HealthTech market. Nelson Advisors LLP: A Specialised Advisory Model for HealthTech Exclusive Dedication to Healthcare Technology Nelson Advisors LLP’s core identity and fundamental source of competitive advantage lie in its exclusive dedication to the healthcare technology sector. This concentrated focus is not merely a marketing claim; it is a strategic business model that enables a deep, nuanced understanding of market dynamics and technological advancements that are critical for successful transactions in this complex industry. The firm's expertise spans a broad range of HealthTech sub-sectors, including Digital Health, HealthTech, Health IT, and Consumer HealthTech. Most notably, Nelson Advisors LLP explicitly specialises in the high-growth, technically demanding and strategically important areas of Healthcare Cybersecurity and Healthcare AI. The firm's reputation as "one of Europe's leading MedTech advisory firms" is explicitly defined as leadership within a "specialised niche" rather than based on overall M&A volume or value across all sectors. This is a deliberate strategic position. By concentrating on a highly regulated and technically complex sector, Nelson Advisors LLP has built a robust knowledge base that is difficult for a generalist firm to replicate. This deep understanding of sector-specific regulatory frameworks, technological advancements and market dynamics provides immense value to clients, especially those navigating the intricacies of international expansion into the UK and Europe. The specialisation serves as a form of risk mitigation against competition from larger, top-tier M&A players and allows the firm to deliver tailored, effective solutions. The "Founders for Founders" Approach: Experience Over Pedigree A key differentiator of Nelson Advisors LLP is its "Founders for Founders" advisory model, which is rooted in the direct entrepreneurial experience of its leadership. The co-founders, Lloyd Price and Paul Hemings, possess a proven track record of building, scaling, and successfully exiting HealthTech businesses themselves. Lloyd Price, for instance, founded and successfully exited Zesty, a patient engagement platform, to a FTSE-listed company. This firsthand, "in-the-trenches" operational experience provides a level of credibility and empathetic understanding that goes beyond traditional advisory services. This practitioner-led perspective is a significant advantage. For a founder navigating a sale or a complex partnership, having an advisor who has personally faced the operational, technological, and emotional challenges of building a business from the ground up can foster a deeper level of trust and confidence. This qualitative, human-centric approach is particularly effective in a relationship-driven industry like M&A, where advice must be not only financially sound but also operationally feasible. The firm's tailored, hands-on approach, with average client engagements lasting between six to nine months, further underscores this commitment to providing bespoke solutions for entrepreneurs, boards, and investors in a rapidly evolving market. This model is especially well-suited for advising early-stage, founder-led companies, for whom a large-scale, generalist firm might feel intimidating or impersonal. The "Build, Buy, Partner, Sell" Framework: A Strategic Compass for UK Market Entry Framework Definition and Strategic Intent Nelson Advisors LLP's strategic value is most evident in its unique "Build, Buy, Partner, Sell" framework.This framework is not a linear process but a comprehensive strategic assessment tool designed to guide clients in maximising shareholder value and investment returns. It moves the advisory relationship beyond a singular transaction, engaging clients in a consultative process to determine the optimal strategic path based on their specific goals and market conditions. This holistic approach is particularly valuable for North American companies considering expansion into the UK, as it addresses a fundamental question: what is the most effective method for entering this new market? The framework's components are applied as follows: Build: This component advises on internal development and organic growth strategies, leveraging a company’s existing capabilities to establish a presence in the UK. Buy: This involves M&A for inorganic growth, such as acquiring an existing UK company to gain new technologies, market share, or talent. The firm assists with buy-side advisory, identifying and evaluating target companies that align with strategic objectives. Partner: This component focuses on forming strategic alliances, joint ventures, or channel partnerships for market expansion, which can be a lower-risk alternative to a full acquisition. Sell: This relates to various exit strategies, including corporate divestitures of non-core assets or the complete sale of a company to maximize shareholder value. The firm's focus on this framework demonstrates a deep understanding of the client's business lifecycle, making the advisory relationship a long-term strategic partnership. Rather than simply reacting to a client's decision, Nelson Advisors LLP proactively helps clients formulate that decision. This model is exceptionally responsive to current market conditions. The research points to a "tighter venture capital funding environment and a dormant IPO market" , which has made M&A a necessary primary exit route for many early-stage HealthTech companies. By emphasising "Seed/Series A Exits," the firm positions itself as a pragmatic and highly relevant advisor for companies that might struggle to secure follow-on funding, offering a crucial alternative path to liquidity. Navigating the UK HealthTech Landscape: Nelson Advisors as a Guide The UK Market Opportunity and Challenges The UK market presents a strategic opportunity for international HealthTech companies, particularly those from North America, due to its proximity to mainland Europe and the established expertise of its logistics and corporate partners. The European HealthTech M&A market in 2025 is also experiencing a "cautious yet discernible rebound", characterised by a "flight to quality" where increasing deal values are observed despite a decline in deal counts.This environment, influenced by significant private equity "dry powder" and the transformative impact of emerging technologies like AI, makes strategic market entry a high-stakes, high-reward endeavor. However, the UK market also presents unique challenges that can impede a successful entry. The research notes that while the UK and US share a language, there are cultural differences to consider, such as a preference for a "more subtle approach" in marketing and a more "consensus-based decision-making process". These cultural norms can lead to a longer sales cycle than what North American companies may be accustomed to. In addition to cultural nuances, companies must navigate the legal and compliance landscape, including registering with Companies House, understanding UK employment law, and complying with taxation requirements like UK corporation tax and Value Added Tax (VAT). The provided research also highlights that certain products or ingredients permitted in the US may be banned in the UK, underscoring the need for specialised regulatory knowledge. Regulatory and Technological Dynamics: The Competitive Edge of Specialisation Nelson Advisors LLP’s deep specialisation is a crucial asset for navigating this complex landscape. The firm’s expertise extends beyond financial transactions to include a profound understanding of the intricate regulatory frameworks governing the HealthTech sector. The European HealthTech market, in particular, is governed by stringent regulations, exemplified by the EU AI Act and the European Health Data Space (EHDS). Paul Hemings, one of the firm's co-founders, also mentions the EU's Medical Device Regulation and In Vitro Diagnostic Regulation as a crucial consideration for MedTech M&A. The firm's advisory role thus becomes a form of regulatory navigation. A successful market entry, whether through M&A or partnership, hinges on compliance with these evolving standards. The ability of Nelson Advisors LLP to assess and value a target company’s regulatory compliance and cybersecurity posture is a critical, non-financial service that directly impacts deal value and the success of post-deal integration. This proactive specialisation distinguishes the firm from those with a more general focus, making it highly relevant for companies operating in these advanced technological landscapes. It demonstrates that the firm serves as a partner in risk management, not just transaction execution, a service that is indispensable for any company seeking sustainable growth in the UK. The Pillars of Expertise: Leadership and Reputation The Founding Partners: A Blend of Entrepreneurial and Corporate Finance Prowess The unique strength of Nelson Advisors LLP is personified by its co-founding partners, Lloyd Price and Paul Hemings, whose combined backgrounds create a powerful strategic synergy. Lloyd Price brings over 12 years of successful HealthTech entrepreneurial experience. He has founded and exited multiple companies, including Zesty, which was acquired by Induction Healthcare Group PLC in 2020 for an estimated £12.7 million. His deep operational knowledge is further evidenced by his roles as a Health Executive in Residence at the UCL Global Business School for Health, a mentor for the Oxford Venture Capital Network, and a founding member of the Digital Healthcare Council. He is also a frequent public speaker and has served as a judge for prestigious industry awards, reinforcing his status as a thought leader. Paul Hemings complements this entrepreneurial background with extensive global M&A and corporate finance expertise. Prior to co-founding Nelson Advisors LLP, he held senior investment banking advisory roles at Credit Suisse, where his transaction experience included over £50 billion in M&A and £40 billion in equity and financing transactions across numerous international markets. He also has a decade of entrepreneurial experience, having founded and exited two early-stage companies. The combination of Lloyd Price's founder-centric perspective and Paul Hemings' high-level institutional finance experience allows Nelson Advisors LLP to bridge the gap between entrepreneurial ambition and institutional requirements. They can provide advice that is both operationally sound and financially sophisticated, effectively connecting early-stage HealthTech companies with large strategic buyers and private equity firms.This unique blend of skills is a significant competitive advantage that distinguishes the firm from both pure-play investment banks and generalist advisory firms. Strong Reputation and Thought Leadership Nelson Advisors LLP has cultivated a reputation as a leading authority in its specialised niche. The firm's credibility is built on its deep knowledge of the HealthTech sector and it actively reinforces this reputation through a robust thought leadership strategy. The partners regularly publish articles and a LinkedIn newsletter that provide "market insights, analysis & predictions". These publications offer valuable intelligence on prevailing trends, such as the increasing role of AI in M&A and the shift toward a "string of pearls" acquisition strategy among major players like Johnson & Johnson MedTech. The firm's partners are frequently sought out for their expert commentary by reputable industry publications like Mergermarket. This public engagement is a deliberate strategy to position the firm as an authoritative voice in the industry. It is a form of business development where prospective clients and partners are drawn in by the firm's demonstrated expertise and valuable content, building trust and credibility long before a formal engagement begins. The firm's involvement in judging industry awards also highlights its respected position within the HealthTech community.This combination of deep, demonstrated experience and proactive engagement in industry discourse reinforces Nelson Advisors LLP's status as an indispensable partner for companies and investors alike. Conclusion & Strategic Implications for Market Entrants The role of Nelson Advisors in UK market entry strategies is defined by a highly specialised, nuanced, and holistic advisory model. The firm is not a generalist M&A broker but a strategic partner exclusively focused on the HealthTech sector. Its value proposition is built on three pillars: Niche Specialisation: The exclusive focus on HealthTech and its sub-segments, especially high-growth areas like Healthcare AI and Cybersecurity, provides a profound understanding of a complex, regulated industry that generalist firms cannot match. Practitioner-Led Expertise: The "Founders for Founders" approach, combining entrepreneurial and corporate finance backgrounds, allows the firm to provide advice that is both financially astute and operationally empathetic, fostering a deeper level of trust and strategic alignment with founder-led companies. Holistic Strategic Framework: The "Build, Buy, Partner, Sell" framework guides clients through a comprehensive assessment of their strategic options, ensuring that a decision to enter the UK market is made in the context of long-term shareholder value and market dynamics. For North American and European companies considering a UK market entry, the implications of this analysis are clear. Nelson Advisors is particularly well-suited for companies seeking a partner who can provide strategic guidance on more than just a transaction. The firm’s deep regulatory knowledge is invaluable for navigating the complexities of the UK and EU compliance landscape. Furthermore, for companies operating in the AI or cybersecurity spaces, a specialised partner with a proven track record is essential for accurately valuing assets and mitigating risks. In a market where a "flight to quality" is increasingly evident, Nelson Advisors LLP's qualitative leadership and specialised expertise offer a compelling alternative to larger, generalist firms, positioning it as a critical ally for achieving sustainable success in the UK HealthTech market. Nelson Advisors > MedTech and Healthcare Technology M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech and MedTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #MedTech#HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us at MedTech and HealthTech industry events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK  NHS ConfedExpo   >  11-12th June 2025 > Manchester, UK  HLTH Europe >  16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate >  25th June 2025, London, UK  HIMSS AI in Healthcare  >  10-11th July 2025, New York, USA Bits & Pretzels >  29th Sept-1st Oct 2025, Munich, Germany   World Health Summit 2025  >  October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit >  October 16th 2025, London, UK  HLTH USA 2025 >  October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 >  10th-13th November 2025, Lisbon, Portugal   MEDICA 2025 >  November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk

MedTech Europe M&A Priorities in 2025 Executive Summary: The Era of Strategic Selectivity The MedTech M&A landscape in Europe in 2025 has shifted fundamentally, moving away from a strategy of broad asset aggregation to one of selective, high-value and strategically aligned investments. This new era of strategic selectivity is defined by a central thesis: acquirers are placing high-conviction bets on mature, innovative companies that offer a clear path to long-term growth and operational efficiency. The market, despite lingering macroeconomic uncertainties, is demonstrating a renewed sense of optimism, propelled by technological advancements and a more permissive regulatory environment. The dominant trends reflect a profound evolution in the industry. Quantitative metrics reveal a notable shift: while the number of transactions has slightly decreased, the total value of these deals has surged, indicating a focus on larger, more substantial acquisitions. The strategic rationale behind these deals is multi-faceted, but three core priorities stand out. First, the pursuit of foundational technology, particularly artificial intelligence (AI) and digital health, is paramount. Acquirers are not merely buying products but are acquiring new, data-driven business models that enable a shift towards holistic and consumer-centric care. Second, regulatory acumen has emerged as a critical strategic asset.The financial and operational burdens of the European Union Medical Device Regulation (EU MDR) and the new EU AI Act are acting as a powerful catalyst for consolidation, creating a competitive advantage for companies with robust compliance infrastructures. Third, acquirers are prioritising market consolidation and vertical integration to achieve economies of scale and enhance operational resilience, particularly in response to geopolitical pressures. The confluence of these factors is shaping a dynamic M&A environment where technological leadership, regulatory foresight and operational excellence are the primary drivers of value. Macro-Level Dynamics & Market Context The New Landscape of European MedTech M&A The MedTech M&A environment in 2025 is undergoing a significant transformation, characterised by a qualitative shift in dealmaking. The market is defined by a move from a high volume of lower-value transactions to a focus on fewer but more substantial, high-value acquisitions. This trend is a clear signal that acquirers are pursuing strategic deals with greater conviction and are willing to deploy significant capital for the right assets. This pattern of strategic selectivity is particularly evident in the deal metrics observed early in the year. Analysis of the first quarter of 2025 reveals a striking divergence between deal volume and deal value. The number of MedTech M&A transactions saw a slight decrease from 62 in Q4 2024 to 57 in Q1 2025. However, during the same period, the total upfront value of these deals increased dramatically, from $2.7 billion to $9.2 billion. This exponential rise in value per transaction is reinforced by a staggering increase in the median upfront payment, which rose from $14 million in Q4 2024 to $250 million in Q1 2025. These figures provide a compelling quantitative snapshot of the market's character, demonstrating a clear focus on high-value investments and acquisitions of more mature companies with deeper product pipelines and established commercial traction. This is a stark contrast to the broad-based asset aggregation that characterised previous periods. Acquirers now appear more willing to pursue singular, large-scale strategic deals that align directly with their core growth priorities, rather than a scattergun approach of accumulating multiple small assets. This trend is expected to continue throughout the year. The investment climate is underpinned by cautious optimism, with experts speculating that potential reductions in interest rates could stimulate investor interest in MedTech assets sooner rather than later. The European digital health market itself is a beacon of growth, valued at $96.68 billion in 2025 and projected to reach over $222 billion by 2030, a powerful indicator of the sector's long-term potential. The confluence of these factors, a more favourable economic environment, selective dealmaking, and strong sector fundamentals—sets the stage for heightened M&A momentum in 2025. Metric Q4 2024 Q1 2025 Number of M&A Deals 62 57 Total Upfront Value $2.7 billion $9.2 billion Median Upfront Payment $14 million $250 million The Evolving Role of Macroeconomic and Geopolitical Factors Beyond the internal dynamics of the MedTech sector, strategic acquirers are increasingly factoring in broader macroeconomic and geopolitical forces that influence operational resilience and market access. These external pressures are not merely headwinds but are actively shaping M&A strategies, forcing companies to prioritise capabilities that were previously considered secondary. A key concern for European MedTech firms in 2025 is the impact of new US tariffs. A study from the consultancy Horváth indicates that these tariffs are disrupting global supply chains, hindering growth projections, and forcing companies to rethink their strategies. For firms that manufacture primarily in Europe, adapting production to a "local for local" principle has become a top priority. This geopolitical pressure creates a distinct new M&A driver. An acquisition target is now not only valued for its innovative product pipeline but also for its manufacturing footprint or supply chain capabilities that can help an acquirer mitigate tariff-related costs and improve operational efficiency. This transforms a simple asset acquisition into a strategic move for supply chain resilience and market access. Deals such as Medical Manufacturing Technologies' acquisition of Comco, a specialist in micro-blasting, exemplify a focus on enhancing processing tools for device manufacturing and operational excellence. Furthermore, global political uncertainty, particularly within the US, can have a significant ripple effect on the European MedTech market. The prospect of regulatory changes to the U.S. Food and Drug Administration (FDA) and the unknown impacts of the pending BIOSECURE Act can influence global investor confidence and may lead to a "wait and see" approach from US-based acquirers in the early part of the year. For a European company, an unclear path to the single largest MedTech market in the world can create a valuation risk. This dynamic presents a compelling opportunity for large European strategic acquirers. A promising, yet potentially undervalued, European target with strong technology but regulatory uncertainty in the US market becomes an attractive acquisition for a large European player seeking to consolidate its position and enhance its portfolio within the EU's single market, a region that is actively working to reinforce its competitiveness and innovation ecosystem. Core Strategic Priorities Priority 1: The Pursuit of Foundational Technology The defining characteristic of MedTech M&A in 2025 is the unwavering focus on acquiring foundational technology that can fundamentally transform business models and patient care. Acquirers are not just buying products; they are buying the underlying intelligence, data, and capabilities that enable a shift towards a more connected, efficient, and personalized healthcare ecosystem. The AI & Digital Health Imperative Artificial intelligence (AI) and digital health platforms are at the absolute forefront of MedTech innovation and remain primary targets for strategic acquisitions. Acquirers are actively integrating AI into their existing product and service offerings to enhance diagnostics, remote monitoring, and data analysis. This is evidenced by a series of high-profile acquisitions in the first half of the year. EssilorLuxottica, for instance, acquired Optegra Clinics to build out its surgical eye care capabilities and power its procedures with AI, demonstrating a clear vertical integration strategy. Similarly, Zimmer Biomet is acquiring Monogram Technologies to expand its surgical robotics portfolio with an AI-driven, personalised orthopaedic surgery platform, signalling its commitment to leading a rapidly growing segment of the market. In a different but equally strategic play, BC Platforms acquired European Real-World Data (RWD) company Medexprim to build a global health data network, recognising that real-world data and evidence analytics are foundational assets for future drug development and precision medicine. The market is rewarding proven AI solutions with a significant valuation premium. Companies with proprietary AI algorithms or scalable platforms that have demonstrated tangible clinical efficacy are commanding revenue multiples of 6-8x, significantly above the sector average of 4.5-5x. This premium is reflective of a deeper strategic goal: to acquire a new business model. The traditional MedTech model, based on a single product sale, is being replaced by a service-based model that offers continuous value. The ultimate rationale for acquiring AI-enabled devices is to capture the long-term data and intelligence they generate. This data can be used to inform future research and development, optimise product performance, and create new, more profitable revenue streams based on continuous patient monitoring and personalised care. The acquisition of a company like Inari Medical by Stryker is a prime example; while Inari's devices treat venous thromboembolism, their true value lies in the real-time procedural and outcomes data they generate, which aligns with Stryker's strategy of integrating procedural intelligence, clinical analytics, and AI-assisted technologies into its surgical platforms. The Focus on High-Growth Therapeutic & Procedural Areas The pursuit of technology is not a scattergun approach; it is highly targeted at specific, high-growth clinical areas that align with an acquirer's core business model. In 2025, M&A activity is heavily concentrated on companies with differentiated procedural capabilities that can be integrated into broader care platforms, with a strong focus on interventional, surgical and chronic care solutions. Interventional & Surgical Solutions: Deals are being driven by companies seeking to expand their portfolios in areas such as surgical robotics, orthopaedics, and vascular intervention. Examples include the acquisition of Biotronik's vascular intervention unit by Teleflex, which strengthens its interventional device portfolio and expands its global reach in catheter-based treatments. Medtronic's acquisition of Nanovis' nano-surface implant technology aims to integrate advanced solutions for spinal fusion devices and address key challenges in spinal surgeries. Neuromodulation & Chronic Pain: With an aging population and a shift towards holistic care, technologies for chronic disease management and pain are key targets. Globus Medical's acquisition of Nevro, a company specialising in spinal cord stimulation for chronic pain, and electroCore's acquisition of NeuroMetrix, which includes a wearable neuro modulation device, underscore this growing focus on innovative pain management solutions. Ophthalmology & Vision Care: Strategic acquisitions in this space are often vertical integration plays. Alcon's acquisition of LumiThera, a photobio modulation device for age-related macular degeneration, expands its non-invasive treatment options for retinal diseases, while its acquisition of LENSAR, Inc., with its femtosecond laser, enhances its cataract surgery capabilities.These deals are part of a broader strategy to secure patient touch points and create more comprehensive, end-to-end solutions. Priority 2: Leveraging Regulatory Compliance as a Strategic Asset In the European MedTech landscape, regulatory acumen has evolved from a simple compliance obligation into a powerful strategic driver for M&A. The complex regulatory environment, particularly the EU MDR and the new EU AI Act, is acting as a catalyst for market consolidation and is a key factor in target valuation. EU MDR as a Market Shaping Force The financial and operational burden of EU MDR and IVDR is fundamentally altering the competitive landscape, creating a distinct divergence between "winners" and "losers". A survey of MedTechs found that half of the organisations planned to spend more than 5% of their annual revenues on MDR compliance, with the most significant costs tied to clinical evaluation and post-market surveillance. The extensive documentation requirements, new classification rules, and the need for continuous post-market clinical follow-up make compliance an expensive and onerous process for many smaller firms. This has forced many small and medium-sized enterprises (SMEs) to make a difficult decision: drop up to a third of their product portfolios rather than incur the costs of re-certification. This challenging environment creates a powerful "buy-side" opportunity for larger, well-resourced strategic acquirers. Companies with robust quality management infrastructures and established regulatory teams can absorb these compliance costs more efficiently. They can acquire promising product portfolios or entire companies that are struggling to meet the new requirements, thereby filling a market vacuum left by competitors. This transforms the regulatory headwind for small firms into a strategic tailwind for larger, more compliant players. For these acquirers, the target company's regulatory capability is as valuable as its intellectual property or market position. The Interplay of the EU AI Act The regulatory complexity for AI-driven medical devices has been compounded by the introduction of the EU AI Act, which complements the existing MDR and IVDR frameworks. The co-application of these regulations means that medical devices containing "high-risk" AI systems must comply with both sets of rules. This creates a multi-layered regulatory roadmap that acquirers must navigate. A company is no longer just buying a device; it is acquiring a complex, multi-layered regulatory challenge. Therefore, a key element of due diligence is now regulatory foresight. A company with not only a cutting-edge AI product but also a clear, well-documented plan for navigating compliance under both regulations is a significantly more attractive and de-risked target. This is especially critical given the risks associated with acquiring a company with legacy certifications. A regulatory expert's analysis notes that a "significant change" during a transaction could invalidate a legacy certificate, leading to a two-year market access disruption that could "completely skew the assumptions underlying the deal". The proactive integration of regulatory expertise into the entire acquisition process, from initial due diligence to post-close integration, has become a competitive differentiator. Strategic Priority Underlying Driver Key Target Characteristics Representative Deal Example Technological Innovation Shift to value-based, data-driven, and consumer-centric care. Proprietary AI algorithms, real-world data platforms, digital health solutions, surgical robotics. Zimmer Biomet-Monogram Regulatory Acumen EU MDR and IVDR compliance burden on SMEs; EU AI Act. Robust quality management systems, clear path to certification under new regulations. (Consolidation Play) Strong players acquiring struggling competitors Market Consolidation Fragmented market, need for economies of scale, supply chain resilience. Specialized product portfolios, established manufacturing capabilities, complementary assets. EssilorLuxottica-Optegra Actionable Insights & Outlook Case Studies: Illustrating the Strategic Rationale The strategic priorities identified in this report are not merely theoretical concepts; they are actively shaping the M&A market and are evident in a number of notable European-relevant acquisitions from the first half of 2025. Acquisitions Driven by Technology & Portfolio Enhancement: Zimmer Biomet's Acquisition of Monogram Technologies: This acquisition is a prime example of a strategic acquirer making a "leapfrog" play into a foundational technology. Zimmer Biomet is not just expanding its robotics suite; it is acquiring an "AI-driven, personalised orthopaedic surgery" platform. The stated goal is to be the "first and only company in orthopaedics to offer a fully autonomous surgical robot," which clearly demonstrates a focus on future strategic positioning over immediate revenue generation. The deal structure, which includes contingent value rights (CVRs) tied to product development and regulatory milestones, further reinforces that the acquirer is valuing future strategic potential and managing the risk associated with its achievement. BC Platforms' Acquisition of Medexprim: This deal illustrates the strategic imperative of acquiring data and analytics as a foundational asset. BC Platforms, a global leader in healthcare data management, acquired Medexprim, a European company specialising in Real-World Data (RWD) and imaging datasets. The rationale is to build the world's largest health data network for precision medicine, enabling seamless access to RWD from every major EU-5 country. This acquisition is not about a physical product but about securing the data assets and expertise necessary for next-generation drug development and personalised medicine. EssilorLuxottica's Acquisition of Optegra Clinics: This transaction is a clear case of vertical integration, a strategy that is gaining traction as companies seek to own more of the patient journey. By acquiring a network of ophthalmic clinics across several European countries, EssilorLuxottica is building out its capabilities in surgical eye care. The clinics provide the necessary operating infrastructure for procedures like cataract surgery and laser vision correction, allowing the company to move beyond its traditional product offerings and power its procedures with AI.This enables the acquirer to secure patient touch points and create a more holistic, vertically integrated business model. Acquisitions for Operational & Supply Chain Resilience: Teleflex's Acquisition of Biotronik's Vascular Intervention Unit: This acquisition, valued at approximately €760 million, is a classic example of a strategic move to consolidate a portfolio and expand global reach. By acquiring Biotronik's unit, Teleflex strengthens its interventional device portfolio with a range of peripheral and coronary products, allowing it to improve treatment outcomes and expand its footprint in catheter-based treatments. The rationale is rooted in both product enhancement and global market expansion. Strategic Recommendations & Outlook The analysis of the European MedTech M&A landscape in 2025 leads to a set of nuanced conclusions for both strategic acquirers and potential target companies. The market has moved beyond a simple numbers game, and success now hinges on a deep understanding of the interwoven dynamics of technology, regulation, and market structure. Strategic Recommendations for Acquirers: Prioritise Proven Technology: Focus on targets that have moved beyond early-stage experimentation to scalable, proven business models. A significant premium is being paid for companies with clinically validated AI solutions and proprietary, data-rich platforms. Due diligence must therefore extend beyond financial metrics to encompass the robustness of a target's AI pipeline and the integrity of its data assets. Conduct Exhaustive Regulatory Due Diligence: The regulatory profile of a target company is now a core financial asset. Acquiring a company without a clear, documented path to EU MDR and EU AI Act compliance is a significant valuation risk that can lead to unexpected delays and market access disruptions. It is imperative to engage with regulatory experts early in the process to assess compliance gaps and their associated costs. Consider Alternative Deal Structures: In a market with elevated valuations and some lingering uncertainty, alternative deal structures such as earn-outs and CVRs are gaining prominence. These structures allow acquirers to mitigate risk and bridge valuation gaps by tying additional payments to the achievement of specific product development, regulatory, or revenue milestones. Seek Operational Resilience: Acquisitions that enhance supply chain resilience, provide a local-for-local manufacturing footprint, or strengthen operational capabilities will become increasingly valuable in a globally fragmented and protectionist environment. Outlook for European MedTech M&A (Late 2025 & Beyond): The MedTech M&A market is poised to maintain its momentum throughout the second half of 2025. The confluence of demographic pressures, the push for digital transformation, and the catalytic effect of regulatory changes creates a compelling environment for strategic deals. The industry is actively seeking to "reimagine regulation not as a constraint, but as a catalyst for innovation", with a greater focus on collaborative approaches to compliance and data management. The market will continue to favor strategic, high-value deals that offer a clear path to long-term growth, operational efficiency, and a differentiated position in the evolving healthcare ecosystem. The most successful acquirers will be those that view acquisitions not just as a means to expand a product line, but as a way to acquire the foundational capabilities and data assets required to lead in the era of digital, data-driven and patient centric healthcare. Nelson Advisors > MedTech and Healthcare Technology M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech and MedTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #MedTech#HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT Contact Us lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us at MedTech and HealthTech industry events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

The Future of MedTech: Building Value for Strategic Acquisitions Executive Summary: The Strategic Convergence of MedTech, Technology and Data The MedTech mergers and acquisitions (M&A) landscape is undergoing a profound and irreversible transformation. The traditional playbook, which long emphasised incremental product improvements and narrowly focused acquisitions, has become largely obsolete. A new era has emerged, defined by the strategic convergence of medical technology, data intelligence, and consumer-centric care models. This report provides a strategic framework for understanding and building value in this rapidly evolving environment, shifting the focus beyond a company's balance sheet to its intangible assets, innovative business models, and operational excellence. Current market dynamics reflect a "flight to quality," with a clear trend toward fewer but larger, high-value deals. The primary drivers of this deal flow are no longer just new devices, but increasingly AI-powered solutions, digital health platforms, and assets that facilitate personalised medicine and direct-to-consumer (D2C) engagement. Value is now intrinsically linked to intellectual property that creates a "competitive moat", business models that generate predictable, recurring revenue from services and data, and operational efficiencies enabled by AI and automation. Navigating this new paradigm requires a heightened level of due diligence. It is no longer sufficient to merely audit financials and legal documents; a thorough assessment of a target's regulatory risk profile, particularly in light of stringent new frameworks like the European Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), is a critical imperative. Similarly, a comprehensive evaluation of the true value and defensibility of a target's IP portfolio is essential. To mitigate risk and bridge valuation gaps in an uncertain economic climate, acquirers are increasingly adopting alternative deal structures, such as earn-outs and licensing agreements. Looking ahead, the competitive landscape is being fundamentally reshaped by cross-sector convergence, with major technology and retail firms building holistic healthcare ecosystems. This is creating a bifurcated market where MedTech companies must either make large, transformative bets or pursue a disciplined "string-of-pearls" strategy with smaller, highly focused acquisitions. The New MedTech M&A Landscape: Trends and Transformations Current Market Dynamics: A Flight to Quality The MedTech market is on a trajectory of significant expansion, with a global valuation of $542.21 billion USD in 2024 and a projected growth to $886.68 billion USD by 2032, representing a compound annual growth rate (CAGR) of 6.5%. This growth, however, is not uniformly distributed. While the industry is expanding overall, M&A deal volume experienced a decline in 2024, yet total deal value either increased or held steady, signaling a clear strategic pivot toward fewer, larger, and more impactful transactions. This trend is highlighted by the dramatic increase in median upfront deal payments, which surged from $14 million in Q4 2024 to $250 million in Q1 2025. This phenomenon is a direct consequence of ongoing macroeconomic pressures, including market volatility and rising interest rates, which make the financing of large, speculative deals more challenging. The market environment has created a scarcity of high-quality assets. The difficult capital environment and heightened risk aversion among investors have led to intense competition for a limited number of "high-growth, at-scale, profitable targets" that have successfully de-risked their business models. A causal relationship exists between this macroeconomic uncertainty and the scarcity of attractive targets. High interest rates and volatile markets make it more difficult for early-stage companies to secure the funding needed to mature, gain regulatory approvals, and demonstrate commercial traction. Consequently, many potential sellers with unproven technologies or incomplete regulatory filings are discouraged from entering the market. The limited pool of de-risked companies, such as those with strong clinical data and FDA clearances, commands a premium valuation from strategic acquirers, leading to larger deal values despite the overall decrease in deal volume. This dynamic creates a "scarcity premium" for truly innovative, mature assets, while a much larger population of early-stage or non-strategic companies struggles to secure an exit. The Strategic Imperative: Beyond Incrementalism For decades, MedTech companies have traditionally relied on incremental product improvements, what some refer to as the "traditional playbook" to drive growth and sustain revenue. This approach is no longer sufficient to compete in a landscape where the healthcare ecosystem is undergoing fundamental change. The future is defined by the need to deliver holistic, high-value solutions that move beyond single product features to improve patient outcomes and enhance care efficiency across the entire value chain. This necessitates a fundamental strategic shift from a product-centric model to a customer-centric mindset, a concept first pioneered in the technology industry by software-as-a-service (SaaS) vendors. M&A has emerged as a primary tool for business transformation, not merely for product acquisition. The evidence suggests that companies are using acquisitions to acquire capabilities or entirely new business models that can fundamentally reshape their operations. Value is shifting from tangible products to "product-enabled services" and "ecosystems" that bring together disparate partners to solve complex problems. To acquire these new models, a traditional MedTech firm cannot simply buy a technology; it must acquire the associated operational infrastructure, talent, and strategic approach. For example, Medtronic's acquisition of Cardiocom, a telehealth and remote monitoring firm, was a strategic move to expand its influence beyond its core medical devices and gain a larger stake in the patient's health journey. Similarly, J&J's acquisition of Shockwave Medical was not just about adding a new device, but about gaining a technology that enables an integrated procedural platform, leveraging data and clinical analytics to enhance its broader portfolio. These deals are not isolated product additions; they are a strategic reorientation of the entire company, making M&A a crucial lever for transformative change in an "accelerated, volatile and interconnected" market. The New Currency of Value: AI, Digital Health, and Personalised Care A. The Centrality of AI and Digital Intelligence Artificial intelligence (AI) has transcended a mere supporting role to become a core driver of value in the MedTech industry. The market for AI in life science analytics is projected to grow substantially, reaching $6.28 billion by 2034, with the MedTech industry as a whole expected to invest over $10 Billion annually into AI by 2025. Acquirers are demonstrating a willingness to pay premium valuations for AI enabled solutions that promise to enhance diagnostics, streamline clinical workflows, and enable more personalised treatment plans.A significant portion of this growth is concentrated in radiology, which currently accounts for approximately 76% of all marketed AI models approved by the FDA. The value proposition of AI is expanding beyond the device itself to the data it generates. A device's value is no longer solely in its physical function but also in its ability to collect, analyse, and monetise data. For instance, Stryker's acquisition of Inari Medical was significantly driven by the fact that Inari’s proprietary thrombectomy devices produce "real-time procedural and outcomes data". This represents a fundamental shift in valuation. The data collected by a device is a new, monetisable asset class that can be used to inform future product design, create new subscription-based service offerings, and provide valuable insights to clinicians. Accordingly, a comprehensive due diligence process must now evaluate a target company’s data collection, management, and analytics capabilities as a separate and critical asset, in addition to the physical device and its intellectual property. B. The Proliferation of Connected Devices and Digital Health Models The demand for wearable medical devices is escalating as consumers increasingly become active participants in their own healthcare. Devices such as continuous glucose monitors (CGMs) and other advanced biosensors enable continuous remote patient monitoring (RPM), which can reduce the need for frequent in-person visits and enable timely clinical intervention. This trend is directly unlocking new business models, particularly direct-to-consumer (D2C) channels that allow MedTech companies to bypass traditional B2B sales to hospitals and doctors and engage directly with the end-user. The ability to connect directly with consumers creates a significant competitive advantage. When a company acquires a target with a D2C channel, it is not just buying a product; it is acquiring a customer relationship and a new, scalable channel. This provides a direct line to consumer insights, allowing for more rapid iteration and deployment of new, software-based services. This strategic advantage is also attracting non-traditional buyers, such as large technology and retail firms like Amazon and Google, which possess an extensive D2C infrastructure and are actively seeking to expand their healthcare ecosystems. C. The Push Toward Personalised and Precision Medicine M&A plays a pivotal role in accelerating the development and delivery of personalised and precision medicine.This approach involves tailoring therapies to individual needs, often based on advanced diagnostics and patient specific data. Strategic acquisitions in this space, such as Illumina's purchase of Grail for early cancer detection and Eden Health's acquisition of a compounding pharmacy, demonstrate a clear focus on building a "closed-loop care model" that controls the entire patient journey. This push toward personalised care is fuelled by a desire to provide more proactive, precise and patient-centred outcomes. The traditional model of one-size-fits-all treatments is being replaced by therapies tailored more closely to individual needs, which is a key growth area for the industry. The New MedTech Value Drivers Value Driver Traditional Approach Modern Approach Business Model Single product sale to hospitals/providers Product-enabled services; D2C engagement; subscription revenue Technology Physical device features and specifications AI-powered diagnostics; connected health platforms; data intelligence Product Focus Broad market appeal; incremental improvements High-growth, niche specialties; personalised/ precision medicine Acquisition Rationale Gaining market share; expanding product portfolio Acquiring new capabilities; accessing a direct patient channel Competitive Edge Product features and sales force reach Intellectual property moat; data assets; regulatory excellence Beyond the Balance Sheet: The Intangible Drivers of Acquisition Value A. Intellectual Property as a Competitive Moat For many MedTech companies, a substantial portion of their overall business value is represented by intangible assets, particularly their intellectual property (IP) portfolio. IP due diligence has evolved from a simple box-checking exercise into a critical strategic tool for evaluating a target's market position and potential risks. Investors and acquirers often view a company's IP portfolio as a proxy for its business value and maturity. A robust and balanced portfolio, which includes patents, trademarks, and trade secrets, signals a well-defended business. The value of IP extends beyond its potential to generate revenue; it also serves a critical risk-mitigation function for the acquirer. A granted patent, especially a mature one that has survived multiple examination cycles, provides "patent office validation" of the core innovation, indicating that it is defensible against competitors and difficult to replicate. This directly de-risks the company's future revenue streams and justifies a higher valuation. A failure to conduct proper IP due diligence can lead to catastrophic errors, such as overpaying for non-exclusive, non-defensible, or legally encumbered IP. Thus, the maturity and quality of a company’s IP portfolio directly correlate with its attractiveness and valuation. The due diligence process must therefore address three fundamental questions: Is the IP valuable in the real world (does it create market exclusivity)? Does the company genuinely own the IP? And what risks are associated with it, such as ongoing litigation, licensing restrictions, or freedom-to-operate issues? B. The Platform-First Approach to Acquisitions A growing trend in the MedTech M&A landscape is the pursuit of platforms, not just products. This strategy is driven by the goal of rapidly integrating new capabilities and creating an interconnected ecosystem that can address complex healthcare challenges. The acquisition is no longer a "bolt-on" addition to a portfolio but a strategic move to integrate a target into the core operational and technological infrastructure of the acquiring company. The acquisitions of Shockwave Medical by Johnson & Johnson and Inari Medical by Stryker are prime examples of this platform-first approach. J&J's acquisition of Shockwave was a strategic move to establish a new "priority platform" with the potential for over $1 Billion in annual sales, complementing its existing portfolio of category-leading cardiovascular technologies. Similarly, Stryker's deal for Inari was driven by the opportunity to acquire a niche technology that provides real-time data, which is highly complementary to Stryker's strategy of integrating AI and clinical analytics into its surgical platforms. This strategic pivot means that a target company is now valued for its ability to enable post-deal synergies, such as streamlined data analytics or supply chain control, which directly enhance the acquirer's core business. This requires a more rigorous due diligence process that assesses a target's operational and technological interoperability to ensure a seamless integration. Navigating the Minefield: Critical Due Diligence for Modern Deals A. Regulatory Due Diligence: A Strategic Necessity The MedTech sector is grappling with an unprecedented regulatory overhaul, most notably with Europe's transition to the more stringent Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR).These changes are fundamentally redefining how MedTech businesses are valued in M&A transactions. For an acquiring company, a robust regulatory due diligence process is no longer optional; it is a critical step for understanding a target’s compliance risk profile and assessing the potential costs of remediation. Failure to do so can lead to expensive post-acquisition surprises, including significant costs for clinical investigations or production process changes. Regulatory compliance, once considered a liability or a mere cost center, is now a strategic asset. A company that has successfully navigated the complex MDR transition and secured early certification gains a temporary competitive advantage, commanding a premium valuation. This is because it has not only de-risked its portfolio but also established a defensible market position against less compliant competitors. Furthermore, organisations that have successfully managed these transitions possess human capital with scarce expertise, making their regulatory talent a significant component of acquisition value. This changes the due diligence process from a simple risk check to a comprehensive value assessment. B. The New Due Diligence Playbook In this new environment, traditional due diligence is insufficient. A modern due diligence playbook must include a thorough IP valuation, an assessment of a target's technology, and a review of its business model. This involves scrutinising intellectual property to ensure it is defensible and creates a competitive advantage, rather than simply confirming its existence. Furthermore, with the proliferation of AI and digital health solutions, due diligence must also evaluate potential risks related to data integrity, AI bias, and data privacy protocols. The introduction of new regulations, such as the EU AI Act, means dealmakers must be forward-looking in their risk assessments and plan for future compliance needs. C. Alternative Deal Structures as a Risk Mitigation Strategy To bridge valuation gaps and manage risk in an economically volatile market, dealmakers are increasingly adopting alternative structures. These include earn-outs, royalties, and co-development partnerships, which tie a portion of the payment to the achievement of specific, measurable milestones, such as successful clinical trial completion or regulatory approval. These structures are particularly well-suited for high-risk, innovation-heavy sectors like biotech and digital health, where the timelines for regulatory approval and commercial success are often uncertain. This flexibility offers a way for both buyers and sellers to mitigate risk and move deals forward even when market conditions are challenging. Critical Due Diligence Checklist for MedTech Acquisitions Due Diligence Area Key Questions Rationale/Value Intellectual Property Does the patent portfolio create market exclusivity? Establishes a defensible competitive moat and protects future revenue streams. Regulatory Compliance Is the company's product portfolio MDR/IVDR certified? Identifies compliance gaps and associated costs; signals a strategic advantage and reduced post-acquisition risk. Technology/AI Is the AI model trained on a diverse dataset to mitigate bias? Addresses ethical concerns and reduces the risk of skewed outcomes, especially in regulated clinical workflows. Business Model Does the business model generate recurring revenue or provide access to a D2C channel? Evaluates long-term value beyond a single product sale and positions the company for future growth and scaling. Data & Privacy Are data integrity and privacy protocols robust and HIPAA/GDPR compliant? Mitigates legal and reputational risk associated with patient data, which is a key asset class for AI-driven solutions. Case Studies in Strategic Success A. Johnson & Johnson's Acquisition of Shockwave Medical In April 2024, Johnson & Johnson announced its acquisition of Shockwave Medical for $13.1 Billion, a significant strategic move within the high-growth cardiovascular intervention market. The rationale behind this deal was to expand J&J's leadership in cardiovascular care by acquiring a highly innovative, minimally invasive technology that addresses a critical unmet patient need. The acquisition of Shockwave, which uses intravascular lithotripsy to treat calcified arterial lesions, was part of a larger, long-term strategy to build a portfolio of "category-leading" segments, following its previous acquisitions of Abiomed and Laminar. The deal created a new "priority platform" with the potential for over $1 Billion in annual sales, underscoring its strategic importance. This deal demonstrates a focus on strategic bets for future growth, even though it was expected to be dilutive to earnings in the short term. B. Stryker's Acquisition of Inari Medical In the first quarter of 2025, Stryker acquired Inari Medical for $4.9 Billion, a transaction that provided Stryker with an entry into the rapidly growing peripheral vascular segment. The deal exemplifies a focused, "singular strategic deal" on a niche, high-growth specialty. The primary value proposition of the acquisition was not solely the physical thrombectomy devices, but rather the fact that Inari's technology generates "real-time procedural and outcomes data". This capability perfectly aligned with Stryker's broader strategy to integrate AI, clinical analytics, and procedural intelligence into its surgical platforms. This case study highlights the strategic shift from a "device-only" acquisition to a "device-plus-data" acquisition, where the data component is as, if not more, valuable than the physical hardware. The M&A playbooks of J&J and Stryker, while both involving large acquisitions, reveal subtle but important differences in strategy. J&J's series of acquisitions in the cardiovascular space, including Shockwave, Abiomed, and Laminar, demonstrate a "portfolio consolidation" strategy. The company is making a series of large, high-value bets to establish and solidify its position as a category leader across multiple high-growth segments. In contrast, Stryker’s acquisition of Inari, while also large, is more a focused entry into a high-growth niche that adds a critical technological capability, data and AI to its existing platform. This indicates that there is no single M&A playbook for large firms; strategies are tailored to the firm's existing strengths, portfolio gaps, and long-term vision. The Future of Value Creation: Recommendations for Stakeholders A. For Acquirers: Building a Resilient M&A Strategy To thrive in the evolving MedTech landscape, acquirers must adopt a new, resilient M&A strategy. The focus should shift from products to capabilities, seeking targets that provide new business models, data platforms, or operational efficiencies, not just new devices. Acquiring a company with a strong D2C channel or a subscription-based service model can unlock new revenue streams and provide a direct link to the end-user. Acquirers must also be prepared to look beyond traditional MedTech firms, as cross-sector convergence with technology and retail giants is reshaping the competitive landscape.Investing in specialised due diligence is paramount; a simple financial audit is insufficient. Rigorous regulatory, IP and AI ethics due diligence are essential to uncover hidden risks and assess a target's true, long-term value. Lastly, leveraging alternative deal structures like earn-outs and licensing agreements can serve as a crucial tool for managing risk and bridging valuation gaps in a volatile market. B. For Targets: Positioning for a Premium Acquisition For MedTech companies seeking a premium acquisition, the focus should be on building a valuable business, not just a sales pitch. The most attractive companies are "bought, not sold". This requires a proactive strategy of de-risking the business through strong clinical data, early regulatory approvals, and demonstrated commercial traction. Cultivating a defensible competitive moat is also critical; investing in a robust and comprehensive IP portfolio that creates market exclusivity and is defensible against competitors can significantly increase a company’s valuation. Prospective sellers must also think like an acquirer by understanding how their product or technology fits into a strategic buyer's long-term vision. The goal is to enhance the acquirer's core business, not to cannibalise it. Finally, mastering the regulatory landscape is a strategic imperative. Early MDR or FDA certification can be a significant competitive advantage that commands a premium valuation. Recommendations for MedTech M&A Stakeholder Key Recommendation Strategic Rationale Acquirers Focus on Capabilities Acquiring a business model or data platform is more transformative than adding a single product. Embrace Cross-Sector Deals The future of healthcare is a convergence of MedTech, technology, and consumer services. Invest in Due Diligence Go beyond financials to assess regulatory, IP, and AI risks for a more accurate valuation. Utilize Alternative Structures Mitigate risk and bridge valuation gaps with flexible deal terms like earn-outs. Targets De-Risk the Company A progressively de-risked startup with strong data and approvals is more attractive and commands a premium. Understand the Acquirer Position the company as a strategic complement to an acquirer's core business. Build a Defensible IP Moat A robust IP portfolio creates market exclusivity and protects long-term value. View Regulatory as an Asset Early compliance and a resilient regulatory framework are now key value drivers. Conclusion: The Evolving Playbook for MedTech Value The future of MedTech M&A is not just about a change in products but a fundamental redefinition of what constitutes value. This value is increasingly intangible, found in data, software, business models, and operational excellence. The old playbook, which focused on a product-centric, incremental approach, is no longer viable. To succeed, stakeholders across the MedTech ecosystem must adopt a new strategic mindset that merges the industry's traditional strengths in engineering and clinical efficacy with the agility and innovation of the technology sector. The companies that can effectively navigate this convergence, embracing AI, data-driven insights and holistic care models, will not only survive but will lead the industry's next wave of growth and value creation. Nelson Advisors > MedTech and Healthcare Technology M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech and MedTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #MedTech#HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT Contact Us lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us at MedTech and HealthTech industry events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands HIMSS AI in Healthcare > 10-11th July 2025, New York, USA World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech companies in the UK, Europe and USA Executive Summary   This report provides a comprehensive analysis of Nelson Advisors LLP, a specialised mergers and acquisitions (M&A) advisory firm with an exclusive focus on the MedTech and healthcare technology (HealthTech) sectors. The firm operates across the UK, Europe and North America, positioning itself as a strategic partner for both innovative HealthTech companies and sophisticated investors. A key finding of this report is the firm's unique value proposition, which is centred on the dual expertise of its founding partners as both successful HealthTech entrepreneurs and seasoned corporate finance professionals. This "Founders for Founders" model offers an unparalleled depth of firsthand industry experience. The firm's advisory approach is further defined by its holistic "Build, Buy, Partner, Sell" framework, which guides clients beyond simple transaction execution toward comprehensive corporate strategies for value maximisation. Nelson Advisors LLP also distinguishes itself as a thought leader, regularly publishing forward-looking market analysis on key trends and valuation dynamics, particularly concerning the impact of emerging technologies like Artificial Intelligence. Nelson Advisors LLP: Core Profile and Strategic Mandate   Mission and Exclusive Focus Nelson Advisors LLP is one of Europe's leading M&A advisory firms, distinguished by its exclusive dedication to the healthcare technology sector. The firm's mission is to empower innovative MedTech and HealthTech companies and strategic investors, providing them with the necessary guidance to navigate the complexities of M&A and achieve their growth ambitions.   This concentrated focus is a deliberate strategic choice that provides a significant competitive advantage over generalist M&A firms. By committing solely to this rapidly evolving sector, the firm can cultivate unparalleled industry knowledge, establish robust relationships, and develop a nuanced understanding of the sector-specific regulatory frameworks, technological advancements, and market dynamics that are crucial for successful MedTech and HealthTech transactions.   "Build, Buy, Partner, Sell" Framework Nelson Advisors LLP employs a unique "Build, Buy, Partner, Sell" framework, which serves as the philosophical foundation for its advisory model. This approach represents a departure from the traditional transactional brokerage model. It is not simply a marketing slogan but a strategic tool for value maximisation. Rather than viewing M&A as a one-size-fits-all solution, this framework allows the firm to conduct a comprehensive assessment of a client's position and recommend the optimal path to maximize shareholder value and investment returns. This includes advising on organic growth ("Build"), strategic acquisitions ("Buy"), channel partnerships and strategic alliances ("Partner"), and exit strategies ("Sell"). This strategic guidance, which is deeply informed by the founders' own entrepreneurial experiences, positions the firm not merely as a transaction facilitator but as a long-term strategic partner dedicated to a client's sustainable success.   Comprehensive Service Offerings The firm provides a comprehensive suite of M&A services tailored to the MedTech and HealthTech sectors. These offerings include:   Buy-side and Sell-side Advisory: Facilitating the acquisition and divestiture of companies. Corporate Divestitures: Assisting companies in selling off non-core divisions. Roll-up Strategies: Advising on the strategic consolidation of fragmented industry segments. Tech Asset Sales: Structuring and executing the sale of specific technological assets. Strategic Advisory Services: Providing guidance on Go-To-Market strategies and international expansion to prepare companies for future transactions and growth.   Leadership and Foundational Expertise   The Power of Dual Expertise: Entrepreneurs as Advisors The core value proposition of Nelson Advisors LLP is rooted in the backgrounds of its founding partners, Lloyd Price and Paul Hemings. Unlike many M&A advisory firms led by professionals with traditional investment banking backgrounds, Nelson Advisors' model is fundamentally different.   Both founders have personally "built, scaled, and exited" their own HealthTech businesses, a rare and compelling attribute for a transactional advisory firm. This firsthand, "in the trenches" experience provides an invaluable layer of insight, empathy, and credibility that a generalist advisor cannot replicate. They have a lived understanding of the complexities and challenges of the entrepreneurial journey, from fundraising and market pivots to securing a successful exit.   This shared experience fosters a deeper level of trust with clients and allows the firm to provide holistic advice that accounts for operational, cultural, and strategic considerations beyond pure financial metrics. This model, often described as "Founders for Founders," serves as a powerful competitive advantage in the market.   Founding Partner Profiles Lloyd Price: As a Partner and Co-Founder, Lloyd Price brings over 12 years of successful HealthTech entrepreneurial experience, including the successful exit of Zesty in 2020 to Induction Healthcare Group PLC. His industry recognition is evidenced by his roles as a judge for the Digital Health Pitchfest and HealthInvestor Awards. He has also served as a panellist and speaker at prominent events and holds non-executive director roles for various UK Digital Health and HealthTech companies. His influence extends to industry policy, having been a founding member of the Digital Healthcare Council.   Paul Hemings: Paul Hemings is also a Partner and Co-Founder, leveraging more than a decade of global M&A and capital-raising expertise. His corporate finance track record includes advising on over $50 Billion in M&A deals and over $40 billion in equity/financing transactions. Like Mr. Price, he has an entrepreneurial background, having founded and exited two early-stage companies, most recently in metabolic HealthTech. He remains an active Board Advisor to several early-stage tech companies, providing a current perspective on the challenges facing founders.   Sectoral and Geographic Specialisation   The "Why" of Exclusive Specialisation   Nelson Advisors' exclusive focus on the MedTech and HealthTech sectors is a deliberate strategic choice that provides a profound advantage over generalist firms. The HealthTech landscape is not a single market but a complex and fragmented ecosystem with rapidly evolving sub-sectors, diverse regulatory requirements, and unique market dynamics. A generalist firm would lack the necessary nuanced understanding of these factors to properly value a company, identify the most strategic buyers, or navigate the specific due diligence challenges.   By concentrating exclusively on HealthTech, Nelson Advisors cultivates unparalleled industry knowledge, builds a robust network of sector-specific buyers, and remains at the forefront of technological and regulatory changes. This specialisation is the key to their ability to deliver superior outcomes for clients.   Deep Dive into HealthTech Sub-sectors The firm's expertise extends across a range of defined MedTech and HealthTech sub-sectors. They provide M&A advisory services for companies in the following areas:   Nelson Advisors LLP: Specialisations by Sub-sector Sub-sector Name Definition Example Technologies / Applications Digital Health Digital technologies used for healthcare and wellness to improve patient engagement and health outcomes. Mobile apps, telehealth platforms, wearable devices, health information tools. HealthTech Technological innovations that enhance patient outcomes and healthcare delivery. Advanced medical devices, AI, robotics, bioprinting, nanotechnology. Health IT Technology for managing, storing, and sharing health information. Electronic health records (EHR), health information exchanges (HIE), clinical decision support tools. Consumer Health Digital tools that enable individuals to proactively manage their own health and wellness. Mobile health apps, smartwatches, fitness trackers, AI-driven wellness solutions. Healthcare Cybersecurity Ensuring the confidentiality and integrity of healthcare information and systems. Protecting medical devices and connected systems from unauthorised access or disruption. Healthcare AI The application of Artificial Intelligence to improve medical diagnosis, treatment, and operational efficiency. Predictive analytics, imaging AI, natural language processing. The founding partners have also specifically built and exited HealthTech businesses in Patient Engagement, Medical Device Cybersecurity, Metabolic Health and Consumer Healthcare, demonstrating a hands-on understanding of these specific markets.   The Global Operational Footprint While the firm maintains a single office location in London, UK, its operational reach is global, covering the UK, Europe, and North America. This lean structure allows for agility and a focus on high-value, high-touch services for complex cross-border transactions.   The founders' extensive corporate finance experience across multiple continents, including the US, UK and Europe, has cultivated a global network of buyers and investors, enabling them to facilitate deals and identify the most suitable global strategic or financial buyers for their clients. Track Record   Collective and Individual Experience The firm's transactional history is primarily represented by the extensive collective and individual experience of its founding partners. Paul Hemings' professional background includes advising on over $50 billion in M&A transactions and over $40 billion in equity/financing transactions.   This experience spans a wide range of industries and geographic locations, including the US, UK, Europe, and Asia, providing a strong foundation for their specialized HealthTech focus.   Founder Exits and Entrepreneurial Track Record A key differentiator is the founders' personal entrepreneurial track record. The partners have built, scaled, and successfully exited four HealthTech businesses, securing exits to North American, European and FTSE-listed companies.   A specific example is the 2020 exit of Zesty, a company founded by Lloyd Price, to Induction Healthcare Group PLC. This direct experience of the exit process provides a compelling form of credibility that goes beyond a standard list of transactions.   Market Insights and Thought Leadership A Proactive, Forward-Looking Perspective Nelson Advisors LLP positions itself as a thought leader in the MedTech and HealthTech M&A space, going beyond the role of a simple transaction facilitator.   The firm actively analyses and disseminates market intelligence through published industry reports and a regular LinkedIn newsletter. This proactive approach demonstrates a commitment to staying ahead of industry trends and providing clients with strategic, forward-looking guidance that accounts for dynamic market conditions. The firm was featured in Deloitte's Q1 2025 M&A update, highlighting its recognition within the industry.   Key Market Trends and Analysis (2025) The firm's reports on the 2025 HealthTech market identify several key macro trends shaping the M&A landscape.   Economic Recovery and Capital Availability: The market is experiencing a "significant resurgence" in mid-2025. This resurgence is attributed to improving macroeconomic conditions, anticipated falling interest rates, and a "substantial pool of pharmaceutical cash reserves". The renewed liquidity is attracting private equity and strategic buyers back into the sector with renewed vigour. AI Integration and Innovation: Artificial Intelligence (AI) is identified as a "mega trend" that is fundamentally transforming healthcare. The firm highlights the rapid maturation of technologies such as Ambient Voice Technology (AVT), which leverages machine learning to automate clinical documentation and provide real-time decision support. This technological evolution is a major driver of deal flow and valuation.   The Nuance of Valuation: A Premium for Innovation The market data presented by Nelson Advisors reveals a nuanced story of a recovering but selective market. There is a divergence between an increasing deal volume and a declining deal count, which indicates a strategic shift towards larger, more significant transactions.   This phenomenon reflects a "flight to quality," where buyers are willing to pay a premium for companies with demonstrable innovation and proven solutions. The data below illustrates how strategic alignment with these mega trends translates to tangible valuation premiums.   HealthTech M&A Valuation Multiples (Mid-2025) HealthTech Sub-sector/Characteristic Estimated Revenue Multiple Companies with Proven AI Solutions 6−8x Companies Aligned with Value-Based Care 5.5−7x Sector Average 4.5−5x   The data proves that the market is not recovering uniformly. A confluence of a thawing market and a persistent strategic imperative for digital transformation is creating an environment where buyers are placing a significant value on companies that address the most critical pain points in healthcare delivery.   This is a critical point for any potential client, as it underscores that their ability to achieve a high-value exit is directly tied to their alignment with these strategic trends, something on which Nelson Advisors is uniquely positioned to advise.   Holistic Value Proposition: Global MedTech and HealthTech M&A landscape   The analysis of Nelson Advisors LLP confirms its position as a highly specialised and distinctive advisory firm within the global MedTech and HealthTech M&A landscape. The firm's competitive advantage is derived from a synergistic blend of core components: an exclusive focus on the dynamic MedTech and HealthTech sectors, a unique founder-led model based on dual entrepreneurial and financial expertise, and a global operational network fuelled by deep industry relationships. Unlike generalist firms, Nelson Advisors offers a profound depth of knowledge and a high-touch, strategic advisory approach embodied in its "Build, Buy, Partner, Sell" framework. The founders’ personal track record of building and exiting companies provides a rare and compelling form of credibility that resonates with entrepreneurs and investors alike. Furthermore, the firm's role as a proactive thought leader, regularly publishing data-driven market analysis, provides a strategic edge by helping clients understand the key trends and valuation dynamics shaping their potential exit or acquisition. In summation, Nelson Advisors LLP is not merely a transaction facilitator but a strategic partner that offers a nuanced and informed approach to value creation in the highly specialised and rapidly evolving MedTech and healthcare technology markets. Nelson Advisors > MedTech and Healthcare Technology M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech and MedTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #MedTech #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us at MedTech and HealthTech industry events   Digital Health Rewired >  18-19th March 2025 > Birmingham, UK   NHS ConfedExpo   >  11-12th June 2025 > Manchester, UK   HLTH Europe >  16-19th June 2025, Amsterdam, Netherlands HIMSS AI in Healthcare >  10-11th July 2025, New York, USA World Health Summit 2025  >  October 12-14th 2025, Berlin, Germany HLTH USA 2025 >  October 18th-22nd 2025, Las Vegas, USA MEDICA 2025 >  November 11-14th 2025, Düsseldorf, Germany Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk

Nelson Advisors invited to judge the Fast Pitch Awards at the Healthcare Summit 2025 Nelson Advisors partners Lloyd Price and Paul Hemings will judge the Fast Pitch Awards at the Healthcare Summit 2025. Introducing the Health Tech Stream An exclusive track spotlighting transformative technologies, next-gen solutions, and early-to-growth stage ventures across: AI diagnostics Digital therapeutics Med tech & devices Remote care platforms Data & predictive analytics Position your brand at the forefront of healthcare transformation. Take the stage at the Fast Pitch 20 tech companies. 5 minutes. One big opportunity. Are you ready to pitch your innovation to a room full of healthcare investors, VCs, and decision-makers? This is your chance to: Pitch live in a rapid-fire, 5-minute format Receive real-time feedback from a panel of expert investors Get handpicked by our investor-driven selection committee Network with high-value partners and industry influencers Applications now open! (Only 20 spots available, which will be categorised between pre and post revenue businesses.) Why you should take part Showcase your brand in front of top-tier healthcare investors. Engage in exclusive networking with decision-makers & potential partners. Position your company at the cutting edge of health innovation. Drive visibility before, during, and after the event through our multi-channel marketing exposure.Nelson Advisors to judge the Fast Pitch Awards at the Healthcare Summit 2025 Fast Pitch Registration Form https://share-eu1.hsforms.com/1R3FqZSdxR-CksG0NC91_rQf7goy Healthcare Summit 2025 The Healthcare Summit is attended by 1,000+ operators, investors and advisors across the health and social care sector. The Healthcare Summit 2025 is run by HealthInvestor UK, part of Nexus Media Group, a leading B2B publishing and events company that focuses on various sectors, including health, social care, seniors housing, education, early years, and property. HealthInvestor UK is one of Nexus Media Group's key publications, offering news, market analysis, and events for the UK healthcare sector. Register for your ticket now! https://lnkd.in/ec9v8d8k Nexus Media Group Nexus Media Group is a publishing and events company, which focuses on the health, education, early-years and property sectors. Our range of established media titles and sector-leading events provide market intelligence and business connections, underpinned by a long-standing commitment to editorial excellence. Established in 2004, our London-based team of journalists and sector experts provide insight and introductions to complex marketplaces. Our extensive calendar of networking events brings together leading decision-makers in the sectors we cover.. Nelson Advisors > Healthcare Technology M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT Contact Us lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands HIMSS AI in Healthcare > 10-11th July 2025, New York, USA World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nelson Advisors featured in the PMLiVE article 'The digital prescription: enhancing the patient experience with technology' Nelson Advisors thought leadership blog ' Healthcare.Digital ' has featured in the PMLiVE article 'The digital prescription: enhancing the patient experience with technology'. Strategies for patient engagement and retention What are some simple wins? Devices – Many of us already rely on and trust wearable devices to track aspects of our health. And it’s only set to get more popular. How’s your step count looking today? By integrating wearables, we get a simple way to engage patients throughout their healthcare journey. Especially with ‘bring your own device’ strategies, making it all the more user-friendly as patients can use what they’re used to. 6 Gamification – In clinical trials, adding a touch of gamification offers a fun and motivating twist to complete assigned tasks, making the experience less of a chore. It also offers a sense of community and support among patients, which we know is absolutely crucial for retention. 7 Personalised health portals – When patients have easy access to their medical records, test results, and other health information, taking an active role in managing health feels doable. These user-friendly portals also allow secure messaging, strengthening communication between patients and healthcare providers. 8 Educational platforms – Knowledge is power. If we give patients the resources to understand their condition, treatment plan, and what to expect, they’re more likely to take ownership of their health. And they’re also likelier to stick to treatment plans set out by their healthcare team. A win, win. 9 Source:: https://pmlive.com/pmhub/cuttsycuttsy/the-digital-prescription-enhancing-the-patient-experience-with-technology/ Nelson Advisors > Healthcare Technology M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide #Divestitures   #Corporate   #Portfolio   #Optimisation   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us @ HealthTech events   Digital Health Rewired > 18-19th March 2025 > Birmingham, UK  NHS ConfedExpo   >  11-12th June 2025 > Manchester, UK  HLTH Europe >  16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate >  25th June 2025, London, UK  HIMSS AI in Healthcare  >  10-11th July 2025, New York, USA Bits & Pretzels >  29th Sept-1st Oct 2025, Munich, Germany   World Health Summit 2025  >  October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit >  October 16th 2025, London, UK  HLTH USA 2025 >  October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 >  10th-13th November 2025, Lisbon, Portugal   MEDICA 2025 >  November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk

Nelson Advisors featured in the Tony Blair Institute for Global Change blog 'The NHS at a Crossroads: The App That Can Transform Britain’s Health' Nelson Advisors thought leadership blog 'Healthcare.Digital' has featured in the Tony Blair Institute for Global Change publication 'The NHS at a Crossroads: The App That Can Transform Britain’s Health' highlighting the scale and importance of Doctolib in the French HealthTech market. Another function of effective patient portals is the ability for patients to conduct administrative functions. This includes the ability to book, cancel and reschedule appointments, initiate referrals and order repeat prescriptions. More sophisticated patient portals allow patients to see real-time appointment availability across services and manage appointments at any time. They can also track the status of referrals and prescriptions, and receive in-app reminders and updates. France’s Doctolib is an example of a private-sector patient portal supporting patients in navigating and coordinating care across a fractured provider landscape. Patients are able to book in-person and virtual appointments, manage prescriptions and communicate with health-care providers. Appointment availability is displayed in real time and patients can receive automated reminders. The platform supports more than 50 million patients and is one of Europe’s leading digital-health platforms. Like the NHS App, Doctolib’s success was accelerated by the Covid-19 pandemic, when the French government selected the company as an official partner to provide support for booking vaccination appointments. Nelson Advisors featured in the Tony Blair Institute for Global Change blog 'The NHS at a Crossroads: The App That Can Transform Britain’s Health' 3. Care Navigation This function allows users to seek advice when they don’t know what health issues they have or who they need to see, which is up to three-quarters of patients with an acute care need. The most advanced AI-powered triage and navigation tools are experts in both the person in question and the relevant local health services available. Based on the information provided by the patient about their condition, the information in the patient’s notes about their background health and the information about local health services, the tool is able to either offer advice on self-care or direct the patient to the most appropriate service first time. This is of huge value to patients and the system, because it improves the quality of care delivered and the efficiency of the health system providing it. In our paper Preparing the NHS for the AI Era: Why Smarter Triage and Navigation Mean Better Health Care analysis by the Tony Blair Institute for Global Change shows that implementing AI across navigation services could free up 29 million GP appointments annually by reducing unnecessary and inefficient pathways to care. TBI also estimates that it would deliver £340 million in productivity gains per year for non-clinical workers via GP and NHS 111 services; this is about one-fifth of the cost of NHS 111. A good example of AI-powered navigation assistants can be found in California, where the Sutter Health app has partnered with Ada, an AI triage and navigation platform. This enables patients to query their symptoms and use probabilistic AI to suggest next steps. Results have shown that 40 per cent of patients have been directed to lower-acuity care and 47 per cent have been navigated away from same-day care. Source: https://institute.global/insights/public-services/the-nhs-at-a-crossroads-the-app-that-can-transform-britains-health Nelson Advisors > Healthcare Technology M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

App Platform Data AI: Maximising HealthTech Value in the next 2 years 1. The Current HealthTech Landscape: A Confluence of Momentum and Opportunity The healthcare industry is in the midst of a profound transformation, driven by the convergence of digital platforms, a growing abundance of health data, and the analytical power of artificial intelligence (AI). This shift is not merely an incremental improvement but a fundamental re-architecture of care delivery, moving toward models that are more proactive, personalised, and efficient. The market for these technologies is expanding at an unprecedented rate, creating a clear and immediate imperative for organisations to define and execute a strategy for value maximisation. An analysis of the market's current trajectory reveals a robust and accelerating growth. The global mHealth apps market, which includes a wide range of mobile health applications, was valued at USD $36.68 billion in 2024 and is projected to reach USD $88.70 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.8% from 2025 to 2032. This expansion is propelled by rising consumer demand for accurate health monitoring solutions and the increasing prevalence of chronic conditions linked to sedentary lifestyles.Meanwhile, the broader digital health market demonstrates an even more resilient and rapid ascent. Valued at USD $180.2 billion in 2023, the market is projected to grow at a substantial CAGR of 25.0% to reach USD $549.7 billion by 2028. This expansion is significantly driven by the widespread penetration of smartphones, tablets, and other mobile platforms, which serve as the conduits for digital health services. The growth was further accelerated by the COVID-19 pandemic, which spurred high adoption rates for virtual care solutions and shifted both consumer and provider attitudes toward remote health services. North America stands out as a clear market leader, commanding the largest share in both the mHealth apps market (30.56% in 2024) and the overall digital health sector. This regional dominance is attributed to a favourable regulatory environment, the early adoption of advanced technologies, and a high concentration of major HealthTech companies. A granular examination of the market dynamics reveals a critical strategic nuance. The difference in growth rates between the mHealth apps market (11.8% CAGR) and the broader digital health market (25.0% CAGR) indicates a key strategic evolution. The most significant value is not being created solely in consumer-facing wellness applications, but in the enterprise-level, behind-the-scenes digital health platforms. The higher CAGR for the broader digital health market highlights that the most impactful investment and value creation are occurring in complex areas such as telehealth, remote patient monitoring systems, and software that streamlines clinical and administrative workflows. This suggests that the strategic imperative is to build platforms that serve the entire healthcare ecosystem, including providers, payers, and patients, rather than focusing on a single consumer touchpoint. For organisations aiming to maximise value, the most fruitful path involves developing solutions that integrate deeply into the professional healthcare infrastructure, enabling a more cohesive and data-driven approach to care delivery. The app platform is emerging as the foundational element upon which this new healthcare ecosystem is built. It is no longer a simple application but a strategic asset that serves as the primary interface for patient and provider engagement, the conduit for collecting real-time health data and the delivery mechanism for AI-powered services. The very performance of this platform is a business-critical concern that extends beyond mere user experience to directly impact clinical outcomes. A glitchy application, a delayed response, or a frozen dashboard can cause serious delays in treatment, a missed medication dose, or a failure to sync a critical biometric reading, each of which can interfere directly with patient care. A 2024 study published in the Journal of Medical Internet Research found that poor technical performance was a top reason for patients abandoning mobile health apps, which in turn meant their care providers no longer received important real-time data. This disruption can result in a delay of treatment adjustments and potentially poorer health outcomes. This relationship between technical reliability and clinical safety is a defining and distinguishing characteristic of the HealthTech sector. It highlights that in this field, technical debt is not merely a financial liability but a potential clinical and ethical risk, underscoring the necessity of a "performance-first" strategy as a matter of patient safety, not just competitive advantage. 2. Defining and Measuring Value in a Digital-First Ecosystem Assessing the value of HealthTech solutions requires moving beyond traditional financial metrics to a more comprehensive, multi-dimensional framework. Value in this sector is not a single number but a composite of four critical dimensions: financial return, user satisfaction, clinical effectiveness, and operational performance. This framework provides a pragmatic and holistic method for quantifying success and justifying investments in a complex and rapidly evolving market. 2.1. A Multi-Dimensional Value Framework The financial dimension remains a crucial component of the value equation. While it can be challenging to measure the return on investment (ROI) for emerging technologies due to a lack of unbiased data, organizations can identify potential financial improvements and track them over time. AI-driven administrative automation, for example, has the potential to save billions of dollars annually by automating tasks such as appointment scheduling, billing, and claims processing. The reduction of hospital readmission rates through patient monitoring solutions is another clear example of direct financial value. New revenue streams can be unlocked through subscription-based models for chronic condition management or by monetizing digital services and data-driven partnerships. For investors and executives, a clear proof of financial ROI is often a prerequisite for a sustained investment. User satisfaction and experience are equally vital, as perceived value directly influences utilisation. This applies to both patients and healthcare professionals. Effective human-centred design is essential for ensuring an optimal experience, but ongoing measurement through consistent surveys is required to validate that expectations are being met. High patient satisfaction scores are directly correlated with improved clinical outcomes and are a powerful indicator of the program’s efficacy. For instance, hospitals with "excellent" patient ratings have achieved significantly higher net margins than those with "low" ratings, demonstrating a clear link between patient experience and business success. A fast and stable application, as previously noted, is not just about convenience; it is fundamental to user engagement, and a poor experience can lead to negative reviews, reduced trust, and user drop-offs, which in turn impacts the entire business model. Clinical effectiveness is arguably the most significant driver of value in HealthTech. This dimension measures the demonstrated improvement in patient health outcomes. While often challenging to measure and reliant on time and volume, showcasing a higher quality of care is the most powerful justification for a program's investment. Success stories, such as Atrium Health's Hospital at Home program, which improved patient outcomes and reduced hospital costs, or Ochsner Health's Connected Maternity Online Monitoring program, which advanced maternal health outcomes, provide compelling evidence of clinical value. AI powered predictive analytics that enable proactive care and earlier disease detection are shifting the paradigm from reactive to preventive medicine, which not only improves patient health but also reduces costs associated with long-term treatments and hospitalisations. Finally, operational performance measures the improvements in efficiency and productivity across the healthcare ecosystem. This includes metrics such as reduced administrative overhead, faster time to diagnosis, and the ability to provide a higher level of care to a broader population with the same number of resources. AI’s ability to automate administrative tasks is a key component of this dimension, with estimates suggesting that up to 45% of these tasks could be automated, leading to billions of dollars in annual savings. By streamlining processes and reducing manual effort, HealthTech platforms enable clinicians to focus on direct patient care, which enhances overall productivity and job satisfaction. 2.2. Quantifying Success: KPIs for Digital Health Platforms To assess the value of a digital health platform, organisations must adopt a set of Key Performance Indicators (KPIs) that align with this multi-dimensional framework. This approach provides a clear and actionable method for benchmarking initiatives, tracking improvements, and demonstrating success to stakeholders. The effectiveness of a digital health platform is fundamentally tied to its technical reliability and performance. This goes far beyond simple user frustration to directly impact clinical safety and business viability. When a platform is glitchy, unreliable, or slow, it can lead to direct disruptions in care. A patient using a remote monitoring app for a chronic condition, such as diabetes, may experience repeated crashes or syncing failures.Over time, this unreliability erodes their trust in the technology and they may abandon the app entirely. When this happens, their healthcare provider loses access to important real-time data, which can result in delays in treatment adjustments and, ultimately, lead to poorer health outcomes. This illustrates that a loss of trust from technical issues can create a negative feedback loop: an unreliable app causes patients to disengage, which leads to a loss of critical data for providers, and this in turn can harm patient care and make the system less effective. Organisations must recognise that a robust, high-performing technical foundation is not merely a competitive advantage but a foundational requirement for patient safety and business viability in the HealthTech sector. 3. The Core Drivers of Value: App, Data, and AI The synergy between a well-designed app platform, high-quality data, and the analytical power of AI is the primary engine for creating value in HealthTech. The platform serves as the delivery mechanism for AI-powered services, which are fueled by the continuous stream of data from users and integrated systems. This combination enables a wide range of use cases that are transforming the healthcare ecosystem. 3.1. The AI-Powered Platform: Use Cases for the Next 24 Months 3.1.1. Enhancing Clinical Care The application of AI in clinical care is rapidly evolving, with a focus on improving diagnostic accuracy and personalising treatment. AI-driven diagnostic tools, powered by machine learning algorithms, can process vast amounts of medical data to detect patterns that may elude human physicians. This is particularly evident in medical imaging, where AI can analyse X-rays, CT scans, and MRIs to identify anomalies with remarkable accuracy. For example, Omron received FDA authorisation for its home blood pressure monitors equipped with an AI-driven algorithm that analyses pressure pulse waves to enhance the early detection of atrial fibrillation (AFib). Similarly, companies like Cleerly use FDA-cleared machine learning algorithms to generate a 3D model of a patient's coronary arteries, helping to identify and quantify plaque to support diagnosis and personalised treatment. Qure.ai leverages AI and deep learning to automate the interpretation of radiology exams, enabling faster diagnosis and treatment. This capability to analyse data more quickly and accurately than human experts, combined with human oversight, has the potential to speed up diagnosis and improve patient outcomes. Beyond diagnostics, AI excels in predictive analytics, which allows healthcare providers to identify high-risk patients and intervene proactively. By analysing a patient’s medical history, lifestyle, and genetic factors, AI can forecast the likelihood of certain conditions and recommend preventive measures, representing a foundational shift from reactive to preventive medicine. 3.1.2. Transforming Patient Engagement and Experience App platforms with integrated AI are revolutionizing the patient experience by enabling continuous and personalized care outside of the traditional clinical setting. Generative AI is being used in remote patient monitoring (RPM) to analyse real-time data from wearable devices and sensors, predict potential health risks, and customise treatment plans. This allows healthcare providers to intervene in a timely manner, reduce unnecessary hospital visits, and enhance overall patient outcomes. AI-powered virtual assistants and chatbots can automate a range of patient-facing tasks, such as providing medication reminders, delivering tailored health tips, and answering common questions. This not only empowers patients with self-management tools but also reduces the workload for healthcare providers, allowing them to focus on more complex clinical interactions. The use of digital tools and AI-driven insights fosters more meaningful connections with patients by breaking down physical access barriers and building trust through genuine patient stories. The ability to offer continuous, personalised care through these platforms is a key value proposition that attracts and retains tech-savvy, health-conscious patients. 3.1.3. Streamlining Operational and Administrative Efficiency The administrative overhead in healthcare is a significant cost driver, but AI can automate a wide range of administrative and operational tasks. A study by McKinsey & Company suggests that AI could automate up to 45% of administrative tasks in healthcare, freeing up USD $150 billion in annual costs. AI-powered algorithms can streamline appointment scheduling, billing, medical coding, and insurance claims processing, reducing the need for manual labor and minimising errors and fraud. Companies like Pieces use generative AI to draft, chart, and summarise clinical notes for doctors and nurses, freeing up valuable time for patient-facing work. Similarly, Microsoft’s Dragon Copilot is an AI healthcare tool that can listen to clinical consultations and automatically create notes. AI also improves data management by handling massive volumes of information and breaking down data silos, connecting disparate data points in minutes, a task that once took years. This improves the speed and quality of decision-making for healthcare providers and contributes to more efficient daily operations. The following table summarises key AI applications and their value propositions. Application Area Specific Use Cases Value Proposition Company/Case Study Examples Clinical Care - Diagnostic Imaging - Predictive Analytics - Precision Medicine - Improved diagnostic accuracy and speed - Proactive, preventive care - Personalized, evidence-based treatment plans - Reduced risk of errors - Cleerly: Non-invasive atherosclerosis measurement - Qure.ai: Automated radiology exam interpretation - AstraZeneca: Early detection of over 1,000 diseases - Omron: AI-driven AFib detection - Insitro: AI-driven drug discovery Patient Engagement - Remote Patient Monitoring - AI Chatbots & Virtual Assistants - Medication Adherence Tracking - Continuous, personalized care - Improved patient access and empowerment - Increased adherence and engagement - Reduced need for in-person visits - Ochsner Health:Connected Maternity Online Monitoring - Huma: Reduced patient readmission rates - Omada Health: Chronic care management with coaching & connected devices - SnapLogic/GenAI App Builder: Automated medication management Operational Efficiency - Administrative Automation - Clinical Documentation - Resource Optimization - Significant cost savings - Reduced staff workload - Streamlined workflows - Faster data access & improved accuracy - Pieces:Generative AI for drafting clinical notes - Microsoft Dragon Copilot: AI for clinical documentation - Google: Suite of AI models for administrative burdens - Elea: Reduced testing and diagnosis times 4. Overcoming the Obstacles: Challenges Impeding Value Maximisation Despite the immense potential, the path to maximising value in HealthTech is fraught with significant and interconnected challenges. These are not isolated technical or ethical issues, but a cascading set of risks that can impede adoption, erode trust, and compromise clinical outcomes. 4.1. Data Fragmentation and Interoperability A foundational barrier to the full potential of AI is the deeply fragmented nature of healthcare data. Medical data exists in various formats, from doctor's notes and X-rays to lab results and wearable device records and is often siloed across disparate systems, making it difficult to exchange and use for AI training. Technical obstacles include the widespread use of proprietary Electronic Health Record (EHR) systems that do not communicate well with each other, hindering seamless data exchange across departments and even within the same hospital. On-premises data storage further complicates matters, presenting significant scalability and integration challenges when attempting to connect with external systems and third-party platforms. Organizational barriers are equally formidable. These include resistance to change, a lack of investment in training, and hierarchical structures that impede cross-departmental collaboration. A major bottleneck is the absence of universal data standards. Even with progress being made, many healthcare providers use customised systems with non-standardised formats, making it difficult to translate and share data effectively. Although federal initiatives such as the CMS Interoperability Framework and the promotion of FHIR APIs are beginning to address these issues, the problem remains a primary hurdle to leveraging data for AI-driven insights. 4.2. Navigating the Regulatory and Ethical Maze 4.2.1. Data Privacy and Security The use of large datasets for training and operating AI models introduces significant privacy risks. Regulations like the Health Insurance Portability and Accountability Act (HIPAA) in the U.S. and the General Data Protection Regulation (GDPR) in Europe set high standards for protecting patient data. However, new risks emerge with AI, including the potential for "anonymous" data to be re-identified by cross-referencing with other sources. There is also the risk of "scope creep" where data collected for one purpose may be used for another without clear consent, and the potential for breaches to occur at an unprecedented scale across multiple connected systems. To mitigate these risks, organisations must implement robust safeguards such as advanced encryption protocols, data anonymisation, and comprehensive risk management strategies. Collaborating with technology partners who are willing to sign Business Associate Agreements (BAAs) and adhere to government-grade security standards is essential. 4.2.2. Algorithmic Bias and Fairness A critical ethical challenge in HealthTech AI is the potential for algorithmic bias. If AI systems are trained on non-representative datasets, they can unintentionally perpetuate or amplify existing healthcare inequities.This can lead to misdiagnosis or suboptimal care for marginalised populations. For instance, a widely used commercial algorithm that was designed to predict healthcare costs rather than illness severity was found to systematically underestimate the care needs of Black patients, as less money is historically spent on them for similar conditions. Similarly, AI models for detecting skin cancer, which were trained predominantly on images of light-skinned individuals, are significantly less accurate when applied to patients with darker skin tones.This demonstrates that AI models are only as unbiased as the data they learn from. Solutions require a multi-disciplinary approach that includes inclusive data collection, continuous monitoring of AI outputs, and the involvement of representatives from underrepresented populations in the development process. 4.2.3. Trust and Transparency Overcoming patient and professional skepticism is paramount to the successful adoption of HealthTech AI. A significant portion of patients feel uncomfortable if a doctor relies on AI, and many believe it could worsen their treatment. A major source of this distrust is the "black box" problem, where the decision-making processes of deep-learning systems are opaque and difficult to interpret, raising concerns about accountability and liability when an error occurs. To build trust, organisations must clearly communicate how AI assists in treatment and emphasise that it is a tool to augment, not replace, human expertise. Transparent policies regarding how patient data is used, clear consent processes, and a commitment to fairness and ethical standards are essential for fostering confidence among all stakeholders. The three primary challenges, data fragmentation, ethical concerns, and trust deficits, are deeply intertwined. The lack of standardised and interoperable data makes it impossible to build large, diverse datasets. This directly leads to algorithmic bias because AI models, lacking representative data, inevitably learn and amplify existing biases present in the limited data they can access. The manifestation of this bias in real-world scenarios, such as misdiagnoses or disparate treatment outcomes, then erodes trust among both patients and clinicians. This creates a negative feedback loop: fragmented data leads to bias, which leads to a loss of trust, which in turn acts as a barrier to collecting the new, more diverse data needed to fix the original problem. A strategic solution cannot be a simple technical fix; it must combine technical interoperability solutions, robust data governance, and transparent, collaborative development processes to rebuild trust and create a more equitable and effective system. App Platform Data AI: Maximising HealthTech Value in the next 2 years 5. Strategic Pillars for Maximising Value in the Next 2 Years Successfully navigating the complexities of HealthTech requires a proactive and multi-faceted strategy. The following pillars provide a definitive roadmap for organizations to not only overcome obstacles but also to transform their digital health initiatives into a source of sustainable value. 5.1. The Business of Digital Health: Monetisation and Partnerships A clear understanding of business models and revenue streams is essential for long-term sustainability. The research highlights two primary models: Healthcare SaaS and Tech-Enabled Services. Healthcare SaaS, similar to traditional cloud software, offers highly recurring revenue, but the total addressable market (TAM) can be smaller, leading to slower sales cycles and lower growth rates compared to the broader tech industry. In contrast, Tech-Enabled Services, which deliver care or navigation support to patients, often have a significantly larger TAM and higher growth rates because they directly address the complex problem of care delivery. They can operate on a fee-for-service, fee-for-value, or subscription basis, providing a flexible and scalable approach. Monetisation strategies extend beyond these core models. Organisations can generate revenue by offering tiered subscription plans with fixed monthly fees, providing flexible care options and recurring revenue streams. Reimbursement opportunities for services like telehealth and remote patient monitoring are also expanding, with both public and private insurers offering pathways for coverage. Data itself can become a monetisable asset; by offering embedded analytics and custom reporting services to outside providers or insurers, organisations can create new revenue sources based on their data assets. Strategic partnerships are another key pillar, as they facilitate data-driven research and open new market and revenue opportunities. 5.2. The Foundation of Interoperability and Data Governance To unlock the full potential of AI, organizations must view interoperability as a core business differentiator, not merely a regulatory or technical hurdle. By strategically investing in interoperability, a company can transform its fragmented data from a liability into a valuable, monetizable asset. This is achieved by moving data out of silos and into a structured, usable format that fuels AI-driven insights. A robust interoperability strategy requires a multi-pronged approach: Adopting Data Standards: Leveraging standards like FHIR APIs and USCDI ensures that data can be exchanged in compatible formats across different systems and organisations. These initiatives provide a foundation for scalable data sharing and a more cohesive healthcare ecosystem. Implementing Semantic Interoperability: This goes beyond simple data transfer to ensure that the data exchanged between systems retains its meaning, regardless of the source. This is achieved by using standardized terminologies like LOINC for lab results and SNOMED CT for clinical findings, ensuring that AI models can interpret data consistently across systems and deliver accurate insights. Establishing Robust Data Governance: A formal, organisation wide framework is essential for managing the entire data lifecycle, from collection to secure destruction. This framework should include clear policies for data accuracy, completeness, and consistency, as well as defined roles and responsibilities for data stewards and trustees. Prioritising critical areas first, such as patient demographics and medication lists, allows for a strategic and scalable approach to governance. 5.3. The Human-AI Partnership: Evolving the Roles of Professionals The future of healthcare is a collaborative partnership between human expertise and AI-powered tools. AI is not designed to replace clinicians but to augment their capabilities, addressing a looming global health worker shortage. AI-powered clinical decision support systems can provide nurses and doctors with valuable insights and evidence-based recommendations, helping them make more informed decisions with higher precision.These systems can also automate administrative tasks, prioritise patient needs, and facilitate seamless communication within a healthcare team, freeing up professionals to focus on direct patient care and improve job satisfaction. To ensure the success of this partnership, strategic initiatives must include cross-functional collaboration from the earliest stages of development, bringing together clinicians, AI scientists, and legal experts. Ongoing training and educational initiatives are crucial to help professionals understand how AI functions, how to interpret its outputs, and how to effectively integrate it into their daily workflows. By proactively fostering a culture of trust and transparency, organisations can ensure that the technology is seen as an ally that enhances care, not an obstacle to it. 6. Case Studies in Value Maximisation: Lessons from the Vanguard Real-world examples demonstrate how a strategic approach to HealthTech, underpinned by the principles of data, platforms, and AI, can lead to measurable and transformative outcomes. These case studies provide valuable lessons for organizations seeking to maximize value in the coming years. 6.1. Atrium Health: The Hospital at Home Model Atrium Health’s innovative Hospital at Home (AH-HaH) program has successfully transformed healthcare delivery by leveraging a strategic partnership with a technology company.The program provides quality care through a combination of in-person and virtual consultations, remote patient monitoring kits, and seamless integration with electronic health records. This approach demonstrates how a digital platform can extend the reach of a hospital beyond its physical walls. The program's success is highlighted by its ability to improve patient outcomes and significantly reduce hospital costs, validating the clinical and financial value of a digitally enabled care model. 6.2. Ochsner Health: Advancing Maternal Care Ochsner Health launched the Connected Maternity Online Monitoring (MOM) program to advance maternal health care in Louisiana and Mississippi. This program uses digital tools to remotely monitor pregnant patients, reducing the need for in-person visits and enhancing both patient experience and operational efficiency. The initiative showcases how a targeted, technology-enabled program can address a specific clinical need and lead to measurable improvements in health outcomes. It underscores the power of a platform-based approach to deliver personalised, proactive care for key populations, serving as a model for other organizations seeking to leverage digital tools to improve specialized care delivery. 6.3. Omron: AI and Hardware Convergence Omron’s strategic moves in 2024 demonstrate a clear vision for maximising HealthTech value through the convergence of hardware, data, and AI.The company received FDA De Novo authorisation for its home blood pressure monitors with an AI-driven atrial fibrillation (AFib) detection algorithm. This innovation enhances the diagnostic capability of a traditional medical device, transforming it into an intelligent tool for proactive health management. Simultaneously, Omron's acquisition of Luscii, a European remote patient monitoring service provider, solidified its presence in digital health and expanded its offerings to include care plans for over 150 diseases. These actions illustrate a powerful strategic approach: instead of relying solely on hardware sales, Omron is integrating AI to enhance its products and acquiring digital services to become a holistic HealthTech player. This validates the importance of a synergistic strategy that combines technological innovation with strategic partnerships and acquisitions to create an integrated ecosystem of care. 7. Conclusion & The Way Forward: A Proactive Roadmap The evidence presented throughout this report makes a compelling case: maximizing HealthTech value in the next two years requires a holistic strategy centred on the seamless synergy of app platforms, high-quality data, and AI. The market is ripe for growth, but success will not be granted to those who simply adopt technology. It will be earned by those who build a connected ecosystem that not only improves patient care and operational efficiency but also proactively addresses the systemic challenges of data fragmentation, ethics, and trust. The most significant opportunities for value creation lie in the enterprise-level digital health solutions that enable a human-AI partnership. By focusing on administrative automation, enhancing clinical decision-making, and transforming patient engagement through remote monitoring, organisations can generate substantial financial returns while delivering a higher quality of care. This will also help to address the looming health worker shortage by freeing clinicians from administrative burdens and allowing them to focus on direct patient care. To capture this value and emerge as a leader, organisations must follow a definitive two-year roadmap: Year 1: Foundation Building The first year must be dedicated to establishing a robust and scalable foundation. This begins with a comprehensive operational audit to identify key data silos and high-impact areas for transformation, such as those with the highest costs or lowest patient satisfaction scores. A multidisciplinary data governance committee should be established with defined roles for data stewards and trustees, tasked with creating clear policies for data quality, access controls, and security. Concurrently, the organisation should prioritise the adoption of standardised terminologies and data exchange protocols like FHIR APIs and USCDI to begin the crucial process of building a semantically interoperable data ecosystem. Year 2: Value Creation and Scaling With a strong data foundation in place, the second year should focus on scaling AI-powered solutions. The strategy should pivot from a technical implementation to a value-driven one, targeting a few high-value use cases that directly address core pain points and demonstrate clear, measurable ROI across all four value dimensions: Financial, User Satisfaction, Clinical Effectiveness, and Operational Performance. This includes implementing solutions for administrative automation, remote patient monitoring, and AI-assisted diagnostics. Furthermore, organisations must invest in a culture of trust by ensuring transparent AI policies and providing ongoing training to professionals to facilitate the human-AI partnership. The window for strategic action is now. The organisations that prioritise the convergence of platforms, data, and AI, while proactively addressing the interconnected challenges of interoperability, ethics, and trust, will be the ones to define the future of healthcare, a future that is more predictive, preventive and personalised for all. Nelson Advisors > Healthcare Technology M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

The Race for Healthcare AI Dominance: Identifying the 'Apple of the Ecosystem' and Future Leader setting de facto standards for AI application, Data Management and Clinical Utility Executive Summary The quest to identify the "Apple of Healthcare AI" is not about finding a company that replicates Apple's consumer-tech closed ecosystem. Instead, this report defines such an entity as one that achieves dominant influence and potential gatekeeping through a highly integrated, user-centric and crucially, interoperable platform. This future leader will set de facto industry standards for AI application, data management and clinical utility. Its command of significant market share will stem from providing indispensable infrastructure and applications, fostering a vibrant partner ecosystem and maintaining stringent control over data privacy and quality. The analysis identifies several major contenders vying for this position. Cloud providers such as Microsoft, Google, and Amazon Web Services (AWS) leverage their foundational cloud infrastructure and extensive AI capabilities. Established medical technology giants like GE HealthCare, Philips, and Siemens Healthineers bring deep domain expertise, device integration, and regulatory experience. Specialised AI and compute innovators, including Nvidia and IBM contribute foundational AI research and high-performance computing. The future "Apple" of Healthcare AI will likely emerge as an "orchestrator" rather than a "monolith." Success will hinge on excelling in data liquidity, robust clinical validation and the seamless deployment of advanced generative AI. Influence will be derived from being the trusted backbone for healthcare data and AI applications, fostering an environment of collaboration and innovation, rather than imposing proprietary lock-in. The "Apple of Healthcare AI" Defined: Ecosystem, Influence and Gatekeeping A dominant, integrated ecosystem in healthcare AI presents characteristics distinct from traditional consumer technology models. While Apple's success in consumer electronics has been largely attributed to its vertical integration and the creation of a tightly controlled, proprietary ecosystem, the healthcare industry operates under fundamentally different principles and pressures. A dominant healthcare AI ecosystem must prioritize interoperability and data liquidity. It would offer a seamless, integrated experience across diverse clinical workflows and patient touchpoints, enabling data flow from various sources such as Electronic Health Records (EHRs), wearables, imaging, and genomics, all while ensuring stringent security and compliance. A critical observation in this domain reveals what can be termed the "Apple Paradox" in Healthcare. The traditional "Apple model" of a tightly controlled, vertically integrated, proprietary ecosystem runs counter to the fundamental needs and regulatory pressures prevalent in healthcare. The industry demands interoperability, data liquidity, and extensive collaboration. Patient data is highly sensitive, fragmented across numerous systems, and subject to stringent regulatory frameworks like HIPAA. A direct application of Apple's closed consumer model to healthcare would inevitably face significant resistance, as healthcare providers and institutions cannot afford to be locked into a single vendor. Such a limitation would severely hinder the data sharing necessary for comprehensive patient care, research, and operational efficiency across disparate departments and external partners. Therefore, the "Apple of Healthcare AI" will not be a replica of Apple's consumer model. Instead, it will be a company that appears to offer a seamless, integrated experience, but achieves this through strategic interoperability and federated data approaches, rather than strict proprietary control. This entity will exert influence through standard-setting and platform convenience, not by locking out competitors entirely. This means the "gatekeeper" role might be more about enabling and orchestrating data flow and AI application, rather than restricting it. Mechanisms of significant influence and potential gatekeeping in AI-driven healthcare will be exerted through control over foundational data infrastructure, such as robust cloud platforms and secure data lakes, as well as through the provision of advanced AI development tools like APIs and foundation models. Widespread adoption of their solutions across various healthcare settings will solidify their position. Gatekeeping would manifest not as outright blocking of access, but as setting the technical and ethical standards for AI deployment, dictating interoperability protocols, and becoming the preferred platform for clinical validation and deployment of new AI applications. Distinguishing consumer tech dominance from healthcare industry leadership is essential. Consumer tech dominance often relies on direct-to-consumer sales, strong brand loyalty and a relatively homogeneous user base. Healthcare leadership, conversely, requires deep integration into complex clinical workflows, adherence to stringent regulatory compliance, the cultivation of long-term institutional partnerships, and a demonstrated ability to consistently improve patient outcomes and operational efficiency. Trust, particularly regarding patient data privacy and security, is paramount in healthcare, far more so than in general consumer technology. Landscape of Key Players in Healthcare AI A. Consumer Tech & Cloud Giants Apple is leveraging its vast install base of iPhones and Apple Watches to expand into consumer health. The company is undertaking a significant overhaul of its Health app, internally codenamed "Project Mulberry," to integrate artificial intelligence and provide users with personalised wellness recommendations, health insights, and educational content. This initiative includes the development of an AI health coach for tailored guidance on fitness, nutrition, sleep patterns, and mental well-being, along with comprehensive food tracking and AI-driven motion analysis. Apple places a strong emphasis on privacy and security, encrypting health data and offering granular user control over shared information. Beyond consumer applications, Apple also supports hospital care efficiency through device integration with EHRs like Epic and facilitates medical research via open-source tools such as ResearchKit and CareKit. Google focuses its healthcare AI efforts on improving operational efficiency, supporting clinicians with AI-driven tools, and delivering personalised patient experiences. DeepMind, an AI company owned by Google, is a key player in AI pharmaceutical R&D, radiology, and imaging. Google Cloud's Healthcare API is designed to be developer-friendly, supporting industry standards like FHIR, HL7v2, and DICOM formats, which enables seamless integration with advanced AI and machine learning tools such as Vertex AI. The company has forged significant partnerships, including one with Quest Diagnostics to streamline services and another with Taiwan's National Health Insurance Administration (NHIA) for transforming diabetes care by leveraging AI to analyse millions of patient records and predict individual risk. Google consistently highlights its commitment to interoperability and open standards. Microsoft stands as a leader in health IT services, with its Azure Cloud becoming a dominant environment for provider-focused software. Microsoft Cloud for Healthcare, notably with the introduction of Dragon Copilot, aims to streamline clinical workflows, documentation, and automate tasks using generative AI trained specifically on healthcare data. Microsoft's strategy involves extensive partnerships with a broad global ecosystem, including major EHR providers (such as MEDITECH, ChipSoft, and Dedalus), system integrators (like Accenture-Avanade), and voice AI companies (such as Canary Speech). The company explicitly outlines its responsible AI principles, emphasising transparency, reliability, safety, fairness, inclusiveness, accountability, privacy and security in its AI development and deployment. Amazon (AWS) provides a centralised hub for health and life sciences data, machine learning tools and partners, with a strong focus on security and compliance, demonstrated by its HIPAA-eligible services and HITRUST CSF certifications. AWS offers purpose-built services tailored for healthcare, including HealthScribe for automatically generating clinical notes via generative AI, HealthLake for securely unifying health data, and Health Imaging for storing, analysing and sharing medical images at petabyte scale.The platform supports Electronic Health Records (EHRs) like Epic on AWS and medical imaging, with a focus on improving clinical intelligence, supporting population health initiatives, and enabling remote patient monitoring. A widespread adoption of "platform" and "marketplace" models is evident across Big Tech and traditional MedTech companies, suggesting a shared understanding that no single company can build all the necessary AI solutions for healthcare. This evolution points towards the rise of "orchestrators" over "monoliths." The inherent fragmentation of healthcare data, stemming from diverse EHRs, imaging systems, and wearables from various vendors, coupled with the need for specialised AI applications across diverse clinical workflows, necessitates a collaborative, platform-centric approach. Success, therefore, lies in providing the underlying infrastructure, tools, and data access that enable a vast ecosystem of partners and developers to build on top. The company best positioned to become the "Apple of Healthcare AI" will likely be the one that builds the most robust, secure, and attractive platform for third-party innovation, rather than attempting to do everything itself. Its influence will stem from becoming the de facto operating system or data backbone for healthcare AI, facilitating data flow and application deployment. This represents a subtle but critical shift from the consumer tech "walled garden" to a healthcare "federated garden." B. Established Medical Technology Leaders GE HealthCare is a trusted global solutions provider with over 125 years of experience in the healthcare sector. The company is a recognised leader in AI-enabled medical device authorisations by the FDA, having topped the list for four consecutive years with 100 authorisations to date. Its digital strategy, known as the D3 framework, emphasises the integration of smart devices, drugs and data, backed by significant research and development investment, totalling approximately $2.2 billion since 2022, aimed at embedding AI into every device. GE HealthCare is actively developing the Edison Digital Health Platform, designed to be a vendor-agnostic hosting and data aggregation platform with an integrated AI engine, explicitly aiming to avoid vendor lock-in for healthcare providers. Furthermore, the company has partnered with AWS to accelerate the development of innovative healthcare applications using generative AI and purpose-built foundation models. Philips leverages AI across a broad spectrum of its offerings, including imaging, diagnostics, therapy, personal health, and connected care solutions. The company's HealthSuite Digital Platform is designed to foster open and collaborative innovation, securely connecting devices and aggregating clinical and consumer data. Philips places a strong emphasis on interoperability standards and offers an Insights Marketplace for curated AI assets, facilitating the adoption of analytics and AI in key healthcare domains. Philips has also partnered with AWS to develop its AI ToolSuite, a scalable, secure, and compliant ML platform on SageMaker, which significantly accelerates machine learning development by reducing training times from weeks to days. Siemens Healthineers is a global leader in AI patent applications within healthcare, holding more than 1,100 patent families related to machine learning, with over 550 rooted in deep learning. The company boasts a portfolio of over 80 AI-powered solutions designed to automate workflows and enhance complex diagnostics.Siemens Healthineers possesses vast medical datasets, including over 750 million curated images and reports, and leverages powerful infrastructure, such as its "Sherlock" supercomputer, for training its algorithms. Its Digital Marketplace provides an open and secured environment for a wide range of healthcare stakeholders to access and deploy digital solutions from both Siemens Healthineers and its partners, supporting various payment models and aiming to digitalise healthcare delivery. A crucial observation in the healthcare AI landscape is the "Clinical Utility" Imperative. The most successful AI solutions in healthcare will be those that demonstrate clear, measurable clinical utility and operational efficiency, directly addressing pervasive issues such as clinician burnout and improving patient outcomes, rather than merely showcasing technical prowess. The healthcare industry is currently grappling with significant challenges, including staff shortages, rising costs, and widespread clinician burnout. These are not just technical difficulties but systemic problems that AI is being positioned to solve. For example, the reported reduction in documentation time for doctors from between seven and eight minutes to under 30 seconds through the use of AI scribes is a powerful illustration of direct, tangible clinical utility. Regulatory bodies, such as the FDA, also play a critical role, with their device authorisations being a significant indicator of a solution's readiness for clinical use. Furthermore, universities are seen as better equipped to evaluate AI technologies in real-world settings, measuring clinical outcomes, quality, safety, and value, which goes beyond mere technical feasibility. The company best positioned to become the "Apple of Healthcare AI" will not simply be a tech company; it will be one deeply embedded in clinical reality, offering solutions that are clinically validated and user-friendly for healthcare professionals. This gives a distinct advantage to traditional MedTech companies, with their existing clinical relationships and regulatory experience, as well as to Big Tech players who successfully forge deep partnerships with healthcare institutions to ensure their AI is truly "clinic-ready" and user-friendly. Trust, built on proven utility and safety, will be a key differentiator in this highly sensitive sector. C. Foundational AI & Compute Innovators IBM's Watson Services market is projected for significant growth, driven by advancements in artificial intelligence, machine learning, and cognitive computing. IBM Watson's AI platform is utilised in the healthcare sector for screening structured and unstructured patient data, accelerating drug discovery, and improving the consistency and overall quality of cancer care. The IBM WatsonX portfolio includes AI chatbots like IBM® WatsonX Assistant for patient services and generative AI capabilities applicable across various enterprise functions within healthcare, such as information security, IT, customer service and product development. Despite its potential, IBM Watson services face challenges, including the need for extensive, time-intensive data structuring and limitations in generating cross-domain insights; for instance, training on oncology data has not provided insights into heart diseases, which restricts its broader clinical deployment. Nvidia, through its venture capital arm NVentures, strategically invests in healthcare startups that leverage AI and machine learning to revolutionise medical practices. Its investment focus areas include drug discovery, medical imaging, personalised medicine, healthcare administration, and remote patient monitoring. Nvidia is actively transforming the healthcare and life sciences industry by forging new partnerships with key players such as IQVIA, Illumina and Mayo Clinic. These collaborations aim to develop advanced AI agents, instruments, and robots for applications in clinical trials, genomics, and digital pathology.Nvidia's core expertise in Graphics Processing Units (GPUs) is directly applicable to AI and machine learning, which are essential for many healthcare applications, thereby creating a vibrant ecosystem around its technology. Beyond these major players, the healthcare AI market is also characterized by a dynamic landscape of numerous specialized AI healthcare companies. These emerging innovators focus on niche areas, such as conversational AI for patient communication (e.g., Voiceoc), handheld ultrasound technology (e.g., Butterfly Network), AI-driven cardiovascular disease detection (e.g., Cleerly), real-time emergency call analysis (e.g., Corti), and AI agents integrated into Electronic Health Records (e.g., Nabla, Autonomise AI). These companies are attracting significant funding, indicating a highly active and fragmented innovation landscape.Many of these specialised firms represent potential acquisition targets or strategic partners for the larger players seeking to expand their capabilities and market reach. Comparative Analysis: Pathways to Ecosystem Dominance A. Data Strategy and Control The approach to data is a critical differentiator among contenders for dominance in healthcare AI. There is a clear divergence between strategies that lean towards proprietary data capture and those that embrace open standards and interoperability. Apple primarily captures consumer health data through its extensive base of devices, including iPhones and Apple Watches and integrates EHR data from connected institutions. While its ecosystem is inherently more controlled and device-centric, Apple does offer the HealthKit API for developers to incorporate user-shared data, albeit with rigorous privacy protocols. In contrast, major cloud providers like Google Cloud, Microsoft Azure, and AWS are built on open standards such as FHIR, HL7v2, and DICOM, and they explicitly emphasise data liquidity. These platforms are designed to aggregate and analyse diverse healthcare data from multiple sources. Similarly, established medical technology leaders like GE HealthCare and Philips advocate for vendor-agnostic platforms and interoperability in their digital health strategies. Access to diverse data types—including wearables, EHRs, imaging, and genomics—varies significantly across players. Apple demonstrates strength in wearable data capture and is expanding into areas like food tracking and workout analysis. Google's focus extends to unstructured data analysis, patient records, and genomics. Microsoft leverages extensive EHR data through its partnerships. AWS provides specialised solutions for genomic, transcriptomic, and other omics data, as well as medical imaging data. Traditional MedTech companies such as GE HealthCare, Philips, and Siemens Healthineers possess deep expertise and vast datasets in medical imaging, encompassing radiology, MRI, PET/CT, and ultrasound. Siemens Healthineers, for instance, boasts over 750 million curated images and reports. IBM screens both structured and unstructured patient data, with a focus on drug discovery and genomics. Nvidia, through its strategic partnerships with companies like Illumina and Mayo Clinic, also demonstrates strong capabilities in genomics and medical imaging. A deeper examination reveals that while access to vast, diverse, and high-quality healthcare data is paramount for training effective AI models, the ability to ethically and compliantly aggregate, de-identify, and make that data actionable is the true differentiator, not merely raw volume. The healthcare industry faces a "data deluge", characterised by fragmentation, varying quality, and extreme sensitivity due to privacy regulations. Simply possessing data is insufficient; it must be usable. The true value lies in the capabilities to aggregate disparate data sources, standardise data into interoperable formats like FHIR, HL7v2, and DICOM, de-identify patient information to protect privacy while enabling analytics and research, ensure robust cybersecurity and compliance (e.g., HIPAA, HITRUST) and ultimately transform raw data into actionable insights that improve care delivery and operational efficiency. Companies that invest in these robust data governance, de-identification, interoperability standards, and secure cloud infrastructure are better positioned. The company best positioned to become the "Apple of Healthcare AI" will be the one that solves the data liquidity and trust problem at scale. Its gatekeeping potential will stem from being the most trusted and efficient conduit for healthcare data, enabling others to build upon it while ensuring privacy and compliance. This positions cloud providers (AWS, Google Cloud, Microsoft Azure) strongly, as they provide the foundational infrastructure for this complex data management, effectively becoming the trusted "data utility" for the entire healthcare AI ecosystem. The following table provides a comparative overview of each major player's approach to data, a critical component of AI dominance. Company Primary Data Sources Data Aggregation / Management Approach Interoperability Stance Key Ecosystem Strategy Apple Wearables (iPhone, Apple Watch), EHRs (via partners) Device-centric, Health app as hub API-driven (HealthKit) Device-centric, Consumer Health Google Patient records, Imaging, Genomics, Unstructured data Cloud Platform (Google Cloud Healthcare API) Open Standards (FHIR, HL7v2, DICOM) Platform-as-a-Service, AI Infrastructure Microsoft EHRs (via partners), Clinical workflows Cloud Platform (Azure Cloud for Healthcare) API-driven, Partner ecosystem Platform-as-a-Service, Enterprise IT Amazon (AWS) Genomic, Omics, Medical Imaging, EHRs (via partners) Cloud Platform (AWS Health Data Portfolio) Open Standards, Purpose-built services Cloud Infrastructure, AI Services GE HealthCare Medical Imaging (MRI, PET/CT), Device data Vendor-agnostic Digital Health Platform Open, Interoperable Medical Devices, Digital Health Platform Philips Imaging, Diagnostics, Patient Monitoring, Personal Health HealthSuite Digital Platform Open Standards, Collaborative Health Technology, Platform-as-a-Service Siemens Healthineers Medical Imaging (750M+ images/reports), Clinical/Operational data Digital Marketplace, Powerful Infrastructure Open, Partner ecosystem Medical Devices, Digital Health Platform IBM Structured/Unstructured Patient Data, Research data Watson AI Platform API-driven AI Solutions, Drug Discovery, Enterprise AI Nvidia Genomics, Medical Imaging (via partners) AI Infrastructure, GPU-accelerated computing Partner-driven AI Hardware, Foundation Models, AI Agents B. Integration and Platform Stickiness The ability to seamlessly integrate hardware and software, coupled with a superior user experience, is a significant factor in achieving platform stickiness. Apple uniquely excels in this regard with its tightly integrated hardware (iPhone, Apple Watch) and software (Health app, iOS), providing a highly cohesive and intuitive user experience for consumer health. Traditional medical technology companies, on the other hand, integrate AI directly into their specialised medical devices, such as imaging systems and diagnostic equipment, enhancing their functionality and efficiency. Cloud giants offer platform-level integration capabilities, enabling third-party applications and EHR systems to connect and interact within their cloud environments, fostering a broader ecosystem. The development of robust developer ecosystems and facilitation of third-party integrations are crucial for widespread adoption. Cloud providers like Google, Microsoft, and AWS actively cultivate vast developer communities through their comprehensive APIs, SDKs, and marketplaces, which in turn enable the creation of a wide range of third-party applications tailored for healthcare. Similarly, GE HealthCare's Edison Digital Health Platform and Philips' HealthSuite Digital Platform are designed to be vendor-agnostic and explicitly support third-party integrations, aiming to create comprehensive digital health ecosystems. Apple's HealthKit API, while more controlled, supports tens of thousands of apps that leverage user-consented health data. This open approach to integration, allowing diverse players to build on a common infrastructure, is a hallmark of the emerging dominant healthcare AI ecosystem. C. Regulatory Acumen and Trust Building Navigating the complex regulatory landscape and building profound trust with healthcare providers and patients are non-negotiable for leadership in healthcare AI. GE HealthCare stands out in this area, having secured 100 FDA AI-enabled medical device authorisations, topping the U.S. Food and Drug Administration's list for four consecutive years. This track record demonstrates a deep understanding of the rigorous requirements for bringing AI solutions to clinical practice. AWS emphasises its commitment to compliance, highlighting its 146 HIPAA-eligible services and HITRUST CSF certifications, which are critical for handling sensitive patient data securely. Microsoft explicitly outlines its responsible AI principles, transparency, reliability and safety, fairness, inclusiveness, accountability, privacy, and security, as foundational to its AI development and deployment in healthcare. Apple also underscores its rigorous scientific validation processes and privacy-centric design for all its health and fitness features. Clinical validation and fostering trust with providers and patients are equally vital. Universities play a crucial role in this regard, as they are often better positioned to clinically validate AI technologies in real-world settings, measuring outcomes that extend beyond mere technical feasibility, such as clinical outcomes, quality, safety, and value in patients' lives. Companies like GE HealthCare, Philips, and Siemens Healthineers, with their long-standing relationships and deep integration with healthcare providers, possess an inherent advantage in building this trust. The rapid adoption of AI scribes, which have been shown to significantly reduce documentation time for clinicians, indicates a growing trust in AI solutions that directly address clinician pain points and demonstrate tangible improvements in efficiency and patient care. This emphasis on proven utility and safety, alongside regulatory compliance, will be a cornerstone for any entity aspiring to lead the healthcare AI sector. D. Innovation Trajectory and Investment The innovation trajectory and investment strategies of key players highlight their commitment to shaping the future of healthcare AI. Big Tech companies are investing heavily in foundational AI, cloud infrastructure, and generative AI applications across various healthcare domains. Google's focus includes operational efficiency, clinician support, and personalised patient experiences, leveraging its Vertex AI and MedLM API. Microsoft is introducing generative AI-powered tools like Dragon Copilot to streamline clinical workflows and documentation, backed by its comprehensive Azure ecosystem. AWS is developing purpose-built foundation models and services like HealthScribe and HealthLake to transform health data into insights. Apple is overhauling its Health app with AI-powered coaching and diagnostics, leveraging its device ecosystem. Established MedTech companies are also making substantial R&D investments. GE HealthCare has invested approximately $2.2 Billion since 2022 to embed AI in every device and develop cloud solutions, focusing on imaging, diagnostics, operational efficiency, and personalised care. Philips applies AI across its imaging, diagnostics, and connected care solutions, while Siemens Healthineers boasts over 80 AI-powered solutions and significant investment in deep learning, leveraging vast medical datasets and powerful computing infrastructure. In the realm of foundational AI, Nvidia is driving innovation in drug discovery, genomics, and advanced AI models through strategic partnerships. The company is developing AI agents, instruments, and robots, leveraging its BioNeMo platform and collaborating with leaders like IQVIA, Illumina, and Mayo Clinic to accelerate research and clinical development. IBM Watson continues to focus on drug discovery, genomics, and cancer care, despite challenges in data structuring. A significant trend observed is the strategic importance of generative AI and foundation models. The shift towards these advanced AI capabilities is a critical accelerant, enabling more versatile and adaptable AI solutions. These models possess the ability to learn from diverse data modalities and apply insights across multiple disease states and tasks. Companies investing heavily in developing or leveraging these advanced AI models will be able to create more powerful and broadly applicable solutions, potentially accelerating breakthroughs in drug discovery, diagnostics, and personalised medicine. The company best positioned to become the "Apple of Healthcare AI" will likely be a leader in developing or deploying these next-generation AI capabilities, thereby enabling a wider range of innovations and potentially setting new industry benchmarks for AI performance and utility. This requires substantial R&D budgets and significant compute power. Collaboration with universities and research institutions is also a recurring theme. Many players recognise the importance of partnering with academic institutions for clinical validation and fundamental research.Universities are seen as particularly well-equipped to evaluate AI technologies in real-world clinical outcomes, moving research from the laboratory into practical application more swiftly. Conclusion The "Apple of Healthcare AI" will not be a monolithic entity that locks down its ecosystem in the traditional consumer tech sense. Instead, it will be an "orchestrator" that defines and enables the most trusted, interoperable, and clinically impactful AI ecosystem. This entity will command influence not through proprietary control, but by setting de facto standards for data liquidity, AI development, and clinical validation. Based on the comprehensive analysis, Microsoft appears to be best positioned to become the "Apple of Healthcare AI." While Apple has a strong consumer base and a privacy-centric approach to personal health data, its primary strength lies in the consumer wearable space, and its traditional "walled garden" model is less suited to the fragmented, interoperability-driven nature of enterprise healthcare. Google and AWS offer robust cloud infrastructure and open standards, making them strong contenders as foundational data utilities. However, Microsoft's strategy demonstrates a more direct and pervasive integration into the existing healthcare enterprise. Microsoft's strengths are multifaceted: Deep Enterprise Integration: Microsoft is a leader in health IT services, with Azure Cloud already a dominant environment for provider-focused software. Its strategic partnerships with major EHR providers (MEDITECH, ChipSoft, Dedalus) and system integrators (Accenture-Avanade) provide unparalleled access to the core clinical workflows and data streams within hospitals and health systems. This direct embedding into the operational fabric of healthcare organizations is crucial for widespread adoption and influence. Generative AI for Clinical Workflow: The introduction of Dragon Copilot, an AI assistant for clinical workflow trained on healthcare data, directly addresses a major pain point: clinician burnout due to administrative burden. Its focus on streamlining documentation, surfacing pertinent information, and automating tasks positions it to deliver immediate, measurable clinical utility, which is a key imperative for adoption. Robust Partner Ecosystem & Openness: While providing a comprehensive suite of tools, Microsoft actively fosters a broad partner ecosystem, allowing ISVs, SIs, and CSPs to build on its Azure AI Foundry and other tools. This approach aligns with the "orchestrator" model, recognising that success lies in enabling others rather than monopolising solutions. The company's commitment to responsible AI principles (transparency, reliability, privacy) further builds the necessary trust in a sensitive industry. Data Strategy and Compliance: Microsoft's cloud infrastructure is designed for secure and compliant handling of healthcare data, providing the foundational environment for data aggregation and AI development without necessarily owning all the data itself. Its emphasis on interoperability standards, while not as explicitly highlighted as Google's or AWS's, is implicit in its enterprise solutions and partnerships. While GE HealthCare, Philips, and Siemens Healthineers hold strong positions in medical devices and imaging, and Nvidia leads in foundational AI computing, Microsoft's combination of deep enterprise presence, direct clinical workflow solutions, robust generative AI capabilities, and a broad, enabling partner ecosystem positions it uniquely to become the central, influential platform—the "Apple"—that orchestrates innovation and sets standards across the diverse landscape of Healthcare AI. Its gatekeeping potential will derive from its indispensable role as the primary platform for AI-driven clinical and operational transformation within healthcare organisations. Nelson Advisors > Healthcare Technology M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk